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ABSTRACT 
The leading cause of malaria infections in humans is the parasite Plasmodium 
falciparum. The parasite contains a non-photosynthetic plastid-like organelle called the 
apicoplast, which is essential for its survival within the host. The apicoplast maintains its 
own genome, which must undergo replication and repair. The only DNA polymerase in the 
apicoplast (apPOL) is classified as an atypical A-family polymerase. apPOL shares no direct 
orthology to mammalian polymerases, making the P. falciparum apicoplast DNA polymerase 
an attractive anti-malarial drug target. We solved the crystal structure of P. falciparum 
apPOL, the first structural representative of the atypical A-family polymerases. We showed 
that apPOL diverges from typical members in two of three previously identified signature 
motifs and a region not implicated by sequence. Moreover, apPOL has an additional N-
terminal subdomain that extends the exonuclease domain. This region may be involved in 
binding DNA, participating in protein-protein interactions, and/or stabilizing the 
proofreading domain. These structural variances may account for functional differences in 
polymerase activity. The crystal structure also provides a point of departure for structure-
based anti-malarial drug design, and these atypical regions could be targeted for potent and 
specific inhibitors. We have developed a fluorescence-based high-throughput DNA 
polymerase assay to screen for compounds that inhibit apPOL activity. Analysis of validation 
experiments indicates that the assay is statistically robust. A pilot screen of a 2,880 
compound library identified 62 possible inhibitors that cause at least 50% inhibition of 
polymerase activity. The simplicity and robustness of the assay provides a solid platform for 
screening apicoplast polymerase inhibitors that could serve as lead compounds in the efforts 
to discover and produce anti-malarial drugs. In addition to its potential as a potent drug 
vii 
target, apPOL provides structural and biochemical insight into a poorly characterized 
subgroup of A-family polymerases. 
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CHAPTER 1 
INTRODUCTION 
Literature Review 
Morgan E Milton and Scott W Nelson 
Modified from a review paper to be submitted for publication in Molecular and Biochemical 
Parasitology. 
Malaria 
Malaria is a devastating disease that affects nearly 200 million people each year (1). In 
2014, approximately 440 thousand children died due to this mosquito-borne disease before 
reaching their fifth birthday (1). The spread of drug-resistant parasites in central Africa, India, 
southeast Asia, and northern South America is a growing problem with common anti-malarial 
drugs such as chloroquine and sulfadoxin-pyrimethamine becoming ineffective (2). Currently no 
drug is available to which some level of resistance has not developed. Even artemisinin, 
discovered by Tu Youyou, who received a Nobel Prize in Medicine in 2015 for her findings, has 
become less effective across southeast Asia and it is only a matter of time before that strain 
makes its way to Africa. The development of new and potent anti-malarial treatments will be 
critical in our ability to continue to combat malaria in the future (1).  
Due to the critical need for new anti-malarial therapeutics, many avenues are being 
explored for their potential as anti-malarial drug targets. The leading cause of malaria in humans 
is Plasmodium falciparum, a member of the phylum Apicomplexa. Apicomplexa houses some of 
the most common and deadly protistan parasites and many members contain an essential 
organelle called the apicoplast, which is exclusive to the phylum (3). Due to its exclusivity to 
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Apicomplexa and its strict requirement for parasite survival, drugs targeted towards apicoplast 
functions should be potent and specific. 
Origins of the Apicoplast 
The apicoplast has had a convoluted history. The presence of an unidentified organelle 
and an extrachromosomal DNA in malarial parasites bewildered parasitologists for over two 
decades. A 35 kb circular DNA was originally observed in 1974 and was thought to originate 
from the mitochondrial genome of the parasite (4). Around the same time, an intracellular 
organelle of unknown function was detected in electron micrographs of different apicomplexans 
(5). Evidence began to build in favor of a plastidic origin of both this “spherical body” and the 
35 kb DNA (6). Nearly 15 years after its misidentification, the true mitochondrial genome of P. 
falciparum was identified (7) and subsequent work showed that the unidentified 35 kb genome 
belonged to what is now known as the apicoplast (8). Full sequencing of the apicoplast genome 
established that its organization and gene content are reminiscent of an algae plastid (9).  
To account for the presence of a plastidic-like organelle which is surrounded by an 
average of four membranes (as appose to the two membranes found in typical plastids), a 
precursor to apicomplexans must have acquired the plastid through a secondary endosymbiosis 
event. The identity of the players involved in the creation of the apicoplast were debated for 
some time, but more recent phylogenetic analysis has provided definitive evidence that the 
apicoplast originated from a photosynthetic red algae (10–12) that was engulfed and retained by 
an ancestral dinoflagellate through a secondary endosymbiosis event (13). The apicoplast has 
since lost its photosynthetic abilities, but is still maintained within the cell presumably due to its 
role in isoprenoid biosynthesis (14). 
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Apicoplast Genome Structure 
The apicoplast genome has low complexity and encodes genes involved in its own 
expression. The apicoplast has one of the most A/T-rich genomes known to date with 86.9% A/T 
(12). It contains 68 genes coding for the large and small subunit rRNAs, a minimal but complete 
set of tRNAs, ribosomal proteins, a bacterial-like RNA polymerase, and several protein 
chaperones (15). A series of inverted repeats contain duplicate genes for rRNAs and tRNAs (12). 
It is believed that the genome has been under high selective pressure, consequently reducing the 
genome from the 150 kb of a typical plastid to 35 kb (15). This has resulted in many deletions 
and rearrangements to conserve the minimal autonomy of the apicoplast (15). This review will 
focus on how the apicoplast genome is replicated and maintained. We will look at each of the 
known proteins involved in replication as well as the proteins that are possibly involved in repair. 
There are still many unknowns in regards to replication and repair of the apicoplast genome. 
Sufficient groundwork has been laid to enable us to begin exploiting this system for new 
antimalarial drugs and we will discuss the potential of these proteins as drug targets.  
Method of Replication 
Understanding the means by which the P. falciparum apicoplast genome is replicated 
could lead to the development of more specific antimalarial compounds with novel mechanisms 
of action. Replication initiates within a large inverted repeat region through twin single-stranded 
displacement loops (D-loops) (16). This method of replication has been shown to be sensitive to 
ciprofloxacin (CIP), a topoisomerase inhibitor (17). At other locations on the genome, replication 
takes place through a rolling-circle mechanism, which is less sensitive to CIP (16). Replication 
of the apicoplast genome initiates in the late trophozoite stage of the parasite life cycle within the 
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red blood cell. Replication begins slightly before that of the nuclear genome and no more than 3 
copies of plastid DNA are observed per cell (16). 
The relationship between D-loop and rolling circle is unclear. When parasites are 
subjected to non-lethal doses of CIP, the amount of 35 kb linear DNA increases but the ratio of 
replication bubbles to replication forks decreases. This suggests the two mechanisms are truly 
theta and sigma varieties and are independent form each other as they are in the plastids of other 
species (16). 
Proteins Involved in DNA Replication 
The genes encoding for the apicoplast DNA proteins reside within the nuclear genome. 
Genome replication requires a helicase to unwind the double-stranded DNA, a primase to 
synthesize RNA primers for Okazaki fragment initiation, and a polymerase to replicate the 
leading and lagging stand templates. Single-stranded binding (SSB) proteins are also essential 
and aid in replication by protecting exposed single stranded DNA, melting DNA secondary 
structure, and interacting with proteins in the replisome. Topoisomerases are required to relieve 
positive supercoils that are generated ahead of the replication fork and are used to separate 
interlocked strands of replicated circular DNA. To date, all of these proteins have been identified 
and to some extend biochemically characterized. This review will examine at what is known 
about each of these proteins and their involvement in the replication and maintenance of the P. 
falciparum apicoplast genome.  
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Figure 1. P. falciparum Prex. Schematic of Prex depicting key motifs as determined by BLAST. A 20 residues 
signaling sequence (yellow) is followed by an apicoplast targeting sequence of unknown length. The fading of 
colors between subdomains represents the unknown cleavage sites between the primase, helicase, and polymerase 
regions. Black bars below the schematic represent the different constructs that have been studied for each region. 
Prex (transcription, transport, and processing) 
The P. falciparum gene PF14_0112 is 6051 bp long, contains no introns, and resides on 
the 14th chromosome of the nuclear genome. It was originally annotated as pom1, for 
“polymerase of malaria,” when a portion of the open reading frame was identified in P. chabaudi 
during a screen for antigenic variation in the murine parasite (18). The gene has since been 
renamed Prex for Plastidic DNA Replication/repair Enzyme Complex (19). Prex is a single open 
reading frame encoding DNA primase, helicase, and polymerase (Fig. 1). A 20 amino acid long 
targeting sequence ensures that the gene is co-translated as a single polyprotein into the ER 
lumen, where it is then transported as a polyprotein into the apicoplast (20–22). Prex is thought 
to contain the only DNA polymerase targeted to the apicoplast, and thus is responsible for both 
DNA replication and repair (23).  
The parasite maintains low levels of Prex expression with the maximum amount 
occurring during the late trophozoite stage, with a subsequent decline in the schizonts stages 
(19). Expression of Prex is correlated with an increase in apicoplast DNA (16), consistent with 
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its proposed role in the replication of the apicoplast genome (Fig. 2). Lindner et al. were unable 
to generate a Prex knockout in P. yoelli (a mouse model for malaria), strongly suggesting Prex is 
an essential protein in the blood stage of parasite infection (24). 
Several groups have shown that the targeting sequence of Prex is specific to the 
apicoplast. Fusing GFP to the Prex targeting sequence causes it to be transported into the 
apicoplast without any transport into other subcellular compartments (19). Subcellular 
localization of Prex was further confirmed when the primase domain was fused to GFP and 
observed throughout the parasite’s life cycle in the red blood cell (24). Using 
immunofluorescence, antibodies to the Prex helicase and apicoplast SSB co-localize to the 
apicoplast in both early and late stages of the parasite’s growth within a red blood cell (25).  
Upon entering the apicoplast, Prex is post-translationally modified by unknown 
protease(s) (20). On the basis of sequence analysis, there are 21 proteases containing predicted 
apicoplast targeting sequences, but their targets and recognition sequences are unknown (26). 
Through Western blot analysis, Seow et al. provided evidence that the polymerase domain is 
separated from the primase and helicase domains (19). Subsequently, Lindner et al. demonstrated 
that the primase domain may sometimes be cleaved from the helicase domain, with cleavage 
products of approximately 55 kDa, 80 kDa, and 160 kDa (24). Antibodies towards the helicase 
Figure 2. Prex Expression Relative to Plasmodia Life Cycle. Apicoplast DNA is replicated in late trophozoites. 
Prex expression is aligns with replication of the apicoplast DNA. Different constructs of the Prex helicase have 
be detected in the ring stage as well as in trophozoites and schizonts. 
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domain resulted in several bands of approximately 70 kDa and 55 kDa (25). Our understanding 
of the Prex post-translational modification is still greatly lacking and is possible that there may 
be several forms of the mature Prex proteins, as multiple isoforms of replicative proteins have 
been observed in the T7 bacteriophage primase/helicase protein (27). It is likely that proteolysis 
is used for regulation of Prex. This regulation would be necessary to obtain the optimal 
stoichiometry of each component, as helicases generally form hexamers, while polymerases act 
as a single subunit (28). Identification of the protease(s) responsible for separating the Prex 
primase, helicase, and polymerase domains would lead to a better understanding of post-
translational modifications of apicoplast proteins, and identify potential targets for drug 
designed.  
Primase 
The Prex primase domain clusters phylogenetically with T7 phage-like primases (19). T7 
bacteriophages contain a bi-functional primase-helicase protein which forms a hexamer with a 
distinct primase and helicase functional domain (29, 30). It is not clear if the Prex primase is 
active when covalently bound helicase like its T7 ancestry, or if primase and helicase domains 
are proteolytically separated. Bacterial primases generally have a three domain organization: 
zinc-binding domain (ZBD), topoisomerase-primase domain (TOPRIM), and a helicase-binding 
domain (HBD). Bacteriophages can have a slight variation in this arrangement, since the helicase 
is expressed with the primase, and thus would have no need for an HBD. Annotation of the Prex 
primase region reveals a ZBD and TOPRIM but no HBD is detected (24). It is possible that the 
Prex primase and helicase are maintained as one protein product after post-translational 
modification or the primase interacts with the helicase in a novel fashion. 
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Seow et al. expressed the primase and helicase domains of Prex together as one 
polypeptide (Fig. 1) and observed Mg2+ dependent primase and helicase activity (19). Lindner et 
al. expressed a protein containing just the primase ZBD and TOPRIM (residues 115 to 465, Fig. 
1) (24). It was found that the PfPrex primase binds zinc in a 1:1 molar ratio and catalyzed DNA 
dependent RNA synthesis, creating > 20 nt long RNA primers in the absence of other replisomal 
components (24). 
Although it is homologous to the T7 helicase-primase, the absence of a HBD, and 
functional studies with the fused protein suggest that the native primase and helicase domains of 
Prex remain as a single unit in the apicoplast, there is also evidence suggesting this may not 
always be the case. Western blot analysis of parasite extract using antibodies to the TOPRIM 
domain revealed a native primase that runs slightly higher than the Lindner recombinant 
construct, suggesting that the primase is cleaved from the helicase. There were other 
predominates band at ~80 kDa and ~160 kDa which could be uncleaved primase-helicase 
domains and larger fragment Prex, respectively (24). 
Due to its essential nature within the replisome, and structural features that set it apart 
from other primases, the Prex primase could serve as a lead target in the efforts towards 
identifying new anti-malarial compounds. Successful high-throughput assays have been 
developed to screen for primase inhibitors in other organisms that could be easily adapted for 
screening the Prex primase (31).  
Helicase 
Like the Prex primase, the helicase clusters with T7 phage-like helicase (19). All 
helicases bind and hydrolyze nucleotides. The Prex helicase has the Walker A and B motifs 
needed for ATPase activity and, due to its homology to the T7 helicase, likely belongs to 
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helicase superfamily 4. Its homology to T7 and the mitochondrial helicase Twinkle, suggests that 
the Prex helicase will form a hexamer ring with single stranded DNA in threaded through the 
center and will translocate along the single-stranded DNA in the 5ʹ to 3 ʹ direction (28).  
The T7 phage-like lineage supports a conjoined primase-helicase domain (32). As 
mentioned above, Western blot analysis has yet to result in a definitive answer regarding the 
post-translational modification of the primase and helicase domains or the native protein 
constructs. Regardless, recombinant expression of separate and functional primase and helicase 
domains has been successful (24, 25). 
Bhowmick et al. expressed the Prex helicase (residues 669-1000, Fig. 1) fused to a 
maltose-binding protein (MBP) tag (25). Even with the MBP-fusion, the helicase was able to 
unwind DNA and the activity was enhanced upon addition of SSB. Using several truncation 
mutants (discussed more below in the SSB section), it was concluded that the C-terminus of the 
P. falciparum SSB (residues 237-256) stimulates Prex helicase unwinding activity (25). The 
potential protein-protein interaction was further characterized in pulldown assays where the 
MBP-tagged Prex helicase pulled-down recombinant and endogenous SSB. To identify the 
domain that was primarily responsible for the interaction, SSB was separated into two domains 
and it was found that an N-terminal construct of SSB (residues 77-200), but not a C-terminal 
construct (residues 200-284) interacted with the helicase (25). It was concluded that the N-
terminus of SSB is likely involved in diverse interactions with the apicoplast helicase and that 
helicase activity is stimulated by the SSB C-terminus (25). It is not known how removal of the 
N-terminal domain of SSB impacts helicase unwinding activity. The Prex helicase was not 
stimulated by non-P. falciparum SSBs, although only Helicobacter pylori SSB, which shares 
25% sequence identity, was tested (25). It should be noted that it is not clear what impact the 
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presence of the MBP has on helicase unwinding activity or protein-protein interactions. While 
Bhowmick et al. carefully showed that the MBP domain itself was not directly responsible for 
their observations, maintaining a large tag (larger than the helicase itself) could affect helicase 
functionality. 
It is common to observe helicases interacting with their SSB counterparts (33, 34). PriA, 
a protein responsible for restarting a stalled replication fork, has been shown to be loaded onto 
the DNA by SSB (35, 36). It is conceivable that the interaction between the Prex helicase and 
SSB could be reminiscent of the PriA-SSB interaction, resulting in the apicoplast SSB acting as a 
helicase loader for the Prex helicase. It is likely that the Prex helicase is a homo-hexameric ring 
that encloses around the single stranded DNA and therefore may require a helicase loading 
protein (29, 37). The T7 helicase and mitochondrial Twinkle helicase are loaded onto the DNA 
without a specific helicase loader, but it is likely that the adjoining primase domain aids in 
loading (37, 38).Thus far, no homolog to a helicase loader has been identified for the apicoplast. 
As seen in T7, it is possible that no helicase loader is present in the apicoplast and that SSB or an 
attached primase domain facilitates the loading for the Prex helicase onto the single-stranded 
DNA. 
Western blots employing polyclonal antibodies raised to the helicase identified two 
prominent bands at 70 kDa and 55 kDa, which were attributed to different helicase isoforms 
similar to what is seen in T7 bacteriophage (25, 39). The 70 kDa band is present throughout the 
blood stage of parasite infection; the 55 kDa band appears during and after the trophozoite stage 
(25). Neither of these bands correspond in size to the Bhowmick et al. recombinant protein, 
which has a theoretical molecular weight of 38 kDa, suggesting that the starting and/or ending 
points chosen for the Prex helicase construct are not those found in the native protein. This 
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highlights the importance of identifying the Prex proteases and their cleavage sites, as the 
functional properties of the native proteins could differ from the truncated counterparts.  
Compounds targeting the Prex helicase would be highly toxic to replication, but due to its 
similarities to the mitochondrial Twinkle helicase, drugs targeted to the apicoplast Prex helicase 
could inhibit mitochondria replication in humans. Drugs designed against the Prex helicase 
would need to be designed to be highly specific to avoid cross reactivity. Assays have been 
successfully developed for high-throughput screening of viral helicase inhibitors (40). These 
assays could possibly be used to identify compounds that inhibit the Prex helicase. 
Polymerase 
The apicoplast DNA polymerase is the best studied of the Prex domains. Genetic analysis 
classifies the polymerase as a prokaryotic A-family DNA polymerase, which are divided into 
five clades: prototypical bacterial PolAs, thermophilic viruses, Aquificaceae and 
Hydrogenothermaceae, Apicomplexa, and other viral-like bacterial polymerases that are found in 
bacteria that also contain typical PolAs (41). There is evidence that the atypical A-family 
polymerase originated through lateral gene transfer when a thermophilic virus infected a 
bacterium, transferring its polA gene to the host. It is likely that the transfer occurred prior to the 
second endosymbiosis event that gave rise to the apicoplast (41). 
Typical PolAs contain a polymerase domain, 3ʹ-5ʹ exonuclease domain for proofreading, 
and a 5ʹ-3ʹ exonuclease domain from removing RNA primers from Okazaki fragments (42). 
Members of Apicomplexa have lost the 5ʹ-3ʹ exonuclease domain, and instead are fused to the N-
terminal primase and helicase domains.  
DNA polymerases often contain accessory proteins that act as processivity factors. 
Currently there is no known processivity factor associated with the apicoplast DNA polymerase. 
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If a processivity factor does exist, it likely will not be similar to known processivity factors since 
no homologs to known processivity factors have been identified. However, based on the 
relatively small size of the apicoplast genome and the time required for its replication, it may be 
possible for apPOL to fully replicate the genome without the assistance of a processivity factor. 
Several labs have biochemically characterized the apicoplast DNA polymerase. One 
complication has been determining the native start site of the polymerase domain as isolation of 
the native polymerase has been unsuccessful. Thus far, three different apicoplast DNA 
polymerase constructs have been studied. Seow et al. first expressed a protein construct 
encompassing residues 1107 to 2016 (Fig. 1), which was named PfPREXpol (19). Kennedy et al. 
employed construct expressing the polymerase domain beginning at residue 1426 (Fig. 1), which 
was referred to as KPom1, based on sequence similarity to the Klenow construct of E. coli Pol I 
(23). Most recently, the Nelson laboratory designed a construct (referred to as apPOL) based on 
the sequence alignment of members of the Plasmodium genus (43, 44) and determined that a 
likely polymerase boundary conserved across Plasmodium spanning residues 1389 to 2016 (Fig. 
1). Below, we will summarize and compare the findings of each group’s apicoplast DNA 
polymerase construct. 
Protein expression levels vary greatly between constructs. PfPREXpol was reported to 
yield 4 mg of purified recombinant protein per liter of culture (19), whereas, the yield of apPOL 
is 50 mg of protein per liter (45). The total yield of KPom1 was not reported and the protein was 
expressed with a maltose-binding-protein (MBP) fusion tag as opposed to the hexa-histidine tags 
used for PfPREXpol and apPOL (23). The MBP fusion tag may serve to increase the solubility 
of KPom1, as we have found that the expression and stability of the apicoplast polymerase is 
very sensitive to modifications at the N-terminal region. Upon solving the crystal structure of 
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apPOL (PDB 5DKU), it became clear why removal of the N-terminal region impacts stability. 
The polymerase N-terminal region forms a long β-hairpin that spans the bottom of the 
exonuclease domain. The β-hairpin and flanking loops are involved in numerous hydrophobic 
and hydrogen bonding interactions with the rest of the exonuclease domain. The start site of 
KPom1 disrupts the β-hairpin and excludes a majority of these interactions, which could result in 
a large unstructured loop at the N-terminus of the construct. It is possible that the differences in 
construct start sites are responsible for the differences in polymerase activity discussed below. 
Biochemical assays examining the polymerase and exonuclease activities, as well as the 
optimal pH, Mg2+ concentrations, and pH have been carried out. PfPREXpol shows maximal 
DNA polymerase activity at a Mg2+ concentration of 4 mM, whereas Kpom1 requires 10 mM 
(reference). KPom1 has pH and temperature optimums of 9.0 and 40°C, respectively, whereas 
PfPREXpol optimum values are 7.0 and 75° C, respectively (19, 23). It is unclear if differences 
in construct alone can account for these discrepancies. The diparity in temperature tolerated by 
the polymerase is particularly interesting. The temperature where PfPREXpol shows the highest 
activity (75° C) is consistent with the thermophilic virus ancestry of the polymerase. On the 
other hand, the temperature optimum of 40°C for KPom1 is more physiologically relevant, as the 
replication of the apicoplast genome takes place in infected red blood cells at 37oC (16). Our 
findings also suggest that apPOL operates at an optimal temperature that is close to 37°C. We 
find that apPOL has a melting temperature of about 45°C and at temperatures higher than 45°C 
the activity significantly decreases and cannot be recovered upon returning to lower 
temperatures. Since the native apicoplast DNA polymerase boundaries are unknown, it is 
difficult to tell what structural features may be causing the differences in temperature tolerance 
observed between PfPREXpol and KPom1/apPOL.  
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Kennedy et al. determined the fidelity of KPom1 and found that it was surprisingly error-
prone, but the exonuclease domain corrected a majority of its mistakes, which is consistent with 
a replicative polymerase (23). They concluded that without an active exonuclease domain, 
KPom1 has a unique error signature error with a mutation spectrum more closely resembling to 
lesion bypass polymerases than replicative polymerases. KPom1 was found to have a strong bias 
towards misincorporating a dGTP across from a dTMP (23), which is in conflict with the A/T-
rich aspect of the apicoplast genome.  
 On the other hand, apPOL behaves more like Klenow and its fidelity is more reminiscent 
of other replicative DNA polymerases (43). Differences in the reported fidelity of KPom1 and 
apPOL may not be solely due the structural variances between the constructs as the methods of 
analysis differed between the two proteins (43). Mutation rates are not exclusively determined by 
polymerase fidelity, as the ability of a polymerase to extend a mismatch and removal of 
misincorporated nucleotides also play a role. Mismatch extension by apPOL is highly sequence 
dependent. The incoming nucleotide must compensate for alternative structures in the 
polymerase active site caused by upstream mismatches. By combining misincorporation, 
exonuclease, and mismatch extension rate data, the most likely mutations caused by apPOL were 
ranked. apPOL is most likely to mutate a G to an A if the downstream base is a T, followed by C 
replacing a T if a T, C, or G is downstream (43). Of course, these observations do not take into 
account potential DNA repair enzymes which could impact mutation probabilities in the 
apicoplast. Also, the high fidelity of apPOL is not reminiscent of a lesion bypass polymerase, in 
fact it is likely that apPOL stalls at common DNA lesions (43). This suggests that DNA repair 
pathways are in place in the apicoplast. 
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Using a complementation assay with heat sensitive Pol I, Kennedy et al. has shown that 
KPom1 can substitute for the E. coli Pol I in vivo. Over expressed KPom1 restored wild-type 
growth by 60%. Induction with IPTG appears to be required, as the no IPTG growth condition 
only restored wild-type growth by 29% (23). Growths were normalized to the growth of Pol I 
containing vectors in the absence of IPTG, suggesting that KPom1 cannot directly replace Pol I 
even though they share nearly identical active site residues. This is potentially due to the 
extremely low kcat of KPom1 but other structural factors could be responsible. 
Polymerases appear to be well-suited for inhibition (46). Drugs developed towards the 
Prex polymerase would likely be potent and specific (47). Seow et al. demonstrated that their 
recombinantly expressed polymerase (PfPREXpol) was sensitive to two drugs known to inhibit 
DNA polymerase activity, chloroquine and suramin, but was unaffected by aphidicolin, an 
inhibitor of the eukaryotic DNA polymerase α (19). A promising high-throughput assay has been 
developed for screening for inhibitors of apPOL (45). The assay is able to detect compounds that 
inhibit polymerase activity through four main mechanisms: DNA mimics/inhibitors that compete 
for the DNA binding site, nucleotide mimics that compete for nucleotide binding site, DNA 
intercalators, and small molecules that inhibit by binding somewhere else on the polymerase. 
Nonspecific inhibitors can easily be counter screened using other DNA polymerases such as Pol 
I. 
Although there is some contradictory data surrounding the details, the results of these 
three groups are in strong favor of the Prex polymerase domain being the polymerase responsible 
for replication of the apicoplast genome. Determination of the native construct would aid in 
understanding the discrepancies in polymerase activities between PfPREXpol, KPom1, and 
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apPOL. Until then, the structure of apPOL will act as a starting point for further understanding of 
this atypical A-family polymerase and aid in the development of new antimalarial compounds. 
SSB 
Single stranded binding proteins (SSB) are responsible for protecting and stabilizing 
ssDNA during replication and repair and melting secondary structures in the DNA. SSBs from 
other organisms have been shown to interact with numerous proteins involved with replication 
and repair (34). The gene encoding the apicoplast SSB resides on chromosome five of the 
nuclear genome and is of bacterial origin (48). Although E. coli SSB shares only a 39% sequence 
identity and 66% homology with P. falciparum SSB, the two proteins share a high degree of 
structural similarity. The N-terminus is composed of an oligonucleotide-binding domain (OBD) 
that facilitates the binding of ssDNA using three tryptophan residues that base stack with the 
DNA (49). P. falciparum SSB maintains the positioning of these residues (48, 50). The OBD 
also contains a conserved histidine that facilitates oligomerization (48, 51). Prokaryotic SSBs 
have an acidic C-terminal tail that is involved in mediating protein-protein interactions in DNA 
replication, repair, and recombination (34). P. falciparum SSB lacks this acid sequence, 
suggesting that its binding partners are different and likely specific to apicoplast function (48, 
52). In addition to having a distinct tail sequence, P. falciparum SSB has a 28 residue extension 
on its C-terminus that has no sequence homology to its E. coli counterpart (48). Removal of 
these 28 residues results in an increase in helicase unwinding activity in the presence of SSB, 
suggesting that the extreme C-terminus of SSB could be involved in helicase regulatory 
functions (25). P. falciparum SSB also contains an N-terminal apicoplast targeting sequence 
believed to be 76 amino acids long (48). 
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Prusty et al. demonstrated that SSB localizes to the apicoplast and that it is expressed 
during all three stages of the parasite’s life cycle in the red blood cell (Fig. 2) (48). Native and 
recombinantly expressed protein form a stable tetramer in solution and in the crystal (48, 49, 52). 
Gel shift assays along with a co-crystal with DNA, confirm that SSB binds ssDNA (48, 49). 
Similar assays with dsDNA show that SSB specifically interacts with ssDNA and that the cause 
of the gel shift is due to SSB binding (48). 
Despite being nearly structurally identical to the E. coli SSB (49), P. falciparum SSB is 
unable to complement E. coli SSB in vivo and removal of the 28 residue C-terminal extension 
does not induce complementation (48). The inability to complement is likely due to the different 
ssDNA binding properties observed in the P. falciparum SSB crystal structure. It is also probably 
that does not bind to the same proteins. While P. falciparum SSB wraps ssDNA with the same 
topology as E. coli, the DNA backbone polarity is reversed (49). There are other notable 
differences between the two proteins: protein-DNA contacts, symmetry of inter-subunit contact 
sites, and protein-protein interactions between adjacent tetramers. P. falciparum SSB only binds 
ssDNA in a tight binding, fully wrapped mode, while E. coli SSB is able to bind in full and 
partially wrapped modes (52). Even in a fully wrapped mode, P. falciparum SSB is able to fully 
diffuse along the ssDNA and melt DNA secondary structures (52). A different interface is 
observed for tetramer-tetramer interactions for P. falciparum SSB than those seen in E. coli. In 
E. coli a loop from neighboring tetramers pack against each other, but this interface is not seen in 
P. falciparum. All of these differences combined could result in an SSB that is functionally 
different from that of E. coli. The findings of Prusty et al. and Antony et al. suggest that the P. 
falciparum SSB may interact with other proteins in a unique manner (48, 49, 52). 
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In the crystal structure of PfSSB, only the residues in OBD (residues 77-194) were 
observed, the C-terminal tail and additional 28 residues had no visible electron density. Analysis 
of the crystals showed that the C-terminal region was at least partially cleaved (49). 
Unfortunately, the crystal structure does not shed light on the helicase binding interaction. 
Antony et al. showed that removal of the extreme C-terminal 28 residues from P. falciparum 
SSB to create a more E. coli-like construct, shifts the binding equilibrium to favor DNA binding 
in a partially wrapped mode (52). An alternative to Bhowmick et al.’s hypothesis that the C-
terminal stimulates helicase activity is that the difference in DNA binding modes of the two SSB 
constructs could impact helicase unwinding activity. Clearly, additional work is necessary to 
determine the precise role of the PfSSB C-terminal region. It appears that this region is 
responsible for novel protein-protein interactions not seen in any other SSB. It is also likely that 
this region is involved in regulation of the ssDNA binding mode and regulation of replication 
partners. 
5ʹ-3ʹ exonuclease 
5ʹ to 3ʹ exonucleases are responsible for removing the RNA primers synthesized by 
primase so that the space can be filled in with DNA and ligated. In typical A-family 
polymerases, an N-terminal 5ʹ to 3ʹ exonuclease domain preforms this activity, but the Prex 
polymerase lacks such a domain and instead has an N-terminal primase and helicase domain 
(41). The 5ʹ to 3ʹ exonuclease domain can function independently of the 3ʹ to 5ʹ exonuclease 
domain and polymerase domain (53). In fact, thermophilic virus PolAs frequently have a 
separate gene which encodes a 5ʹ to 3ʹ exonuclease (41). We have identified the putative 
apicoplast targeted 5ʹ to 3ʹ exonuclease on chromosome 7 of the nuclear genome of P. 
falciparum (gene ID Pf3D7_0203900). BLASTP analysis reveals a DNA Pol I 5ʹ to 3ʹ 
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exonuclease domain with metal binding sites. We propose that this is the 5ʹ to 3ʹ exonuclease 
involved in DNA replication within the apicoplast and will act in conjunction with the Prex 
polymerase. 
Potential for Anti-malarial Drug Target 
Since its discovery as a unique and essential organelle, the apicoplast has been 
investigated for its potential as a target for anti-malarial compounds (17). It was observed that 
antibiotics that affect protein or nucleic acid synthesis have anti-malarial activity. Interestingly, 
these compounds induced a “delayed-death” phenotype (17, 47). Delayed-death refers to the 
phenomenon that upon administration of the drug, the first generation of parasites remain viable, 
continuing to divide and infect new red blood cells but the second generation is unable to form 
functional merozoites (54). Parasites treated with doxycycline, which inhibits the 70 S ribosome, 
cannot replicate their apicoplast genomes and were thus nonfunctional. Interestingly, the 
mitochondria is left unaffected (54). This suggests that drugs are able to penetrate the four 
membranes encompassing the apicoplast and impact proteins involved in apicoplast replication 
and transcription.  
Current drugs that impact replicative proteins 
Many antibiotics inhibit proteins involved in transcription and translation of the 
apicoplast genome: tetracycline, clindamycin, azithromycin, and rifampin (17, 55). Ciprofloxacin 
and coumermycin inhibit the DNA gyrase of the apicoplast (56, 57) and the Prex polymerase is 
inhibited by chloroquine and suramin (19). Unfortunately, these drugs are not specific to the 
apicoplast and frequently have high IC50s. More potent and specific compounds need to be 
identified. 
20 
Medicine for Malaria Venture assembled a library of 400 compounds identified through 
phenotypic screening that inhibit malaria. This library, known as the Malaria Box, is refined 
from 20,000 compounds identified from four million compounds screened by St. Jude’s 
Children’s Research Hospital, Novartis, and GlaxoSmithKline (58). All compounds inhibit 
malaria in the blood stage and are nontoxic to humans. Bowman et al. identified roughly 40 
small molecules from the Malaria Box that have an apicoplast-targeting phenotype (59). We 
have found that one of these 40 compounds likely inhibits the Prex polymerase. The small 
molecules within the Malaria Box will provide a solid starting point for developing new anti-
malarial therapies, but a phenotypical screen sometimes misses the potential of some potent 
targets. 
The replication proteins mentioned in this review could be potent and highly specific 
drug targets. There may be the concern of cross-reactivity between DNA ligase, SSB, and Prex 
helicase and human cellular functions but it is likely that apicoplast-specific features could be 
exploited. Efforts to identify inhibitors of the Prex polymerase are underway (45). As we gain 
more biochemical and structural knowledge concerning the proteins involved with replication 
and maintenance of the apicoplast genome, we begin to elucidate key features that can be 
employed in our efforts in anti-malarial drug discovery. 
Dissertation Organization 
This work focuses on the structure and biochemical mechanisms of the Plasmodium 
falciparum apicoplast DNA polymerase (apPOL), centering on its “atypical” nature and potential 
use as an antimalarial drug target. Since apPOL has no direct orthologs to mammalian 
polymerases, the P. falciparum apPOL is an attractive antimalarial drug target that provides 
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structural and biochemical insight into a poorly characterized subgroup of the A-family 
polymerases.  
Chapter two concentrates on the initial crystallization process, data collection, and 
solving of the apPOL x-ray crystallography structure. Due to the small dimensions of the 
crystals, tendency towards disordered crystal packing, and lack of a close structural homolog for 
molecular replacement, data collection and processing posed a significant challenge. Advances 
in synchrotron beamline technology through the use of a mini-beam allowed for the collection of 
a full data set on a single apPOL microcrystal. Due to complications with traditional molecular 
replacement, MR-Rosetta was employed to solve the structure of apPOL. MR-Rosetta couples 
traditional x-ray crystallographic software with structure prediction algorithms, resulting in 
energy-optimized models that can improve electron density maps. The work published in this 
paper focuses on the technical aspects of data collection and processing and lays the groundwork 
for the structural characterization of apPOL. 
The structure of the apicoplast DNA polymerase, the first of an atypical A-family DNA 
polymerase to be solved, is presented in chapter three. apPOL contains the canonical right 
handed finger, thumb, and palm subdomains seen in all polymerases. Although apPOL resembles 
a typical A-family polymerase, a close inspection reveals several distinct structural features. This 
paper compares structural and active site elements of apPOL with other structurally characterized 
A-family members. Several of the structural differences between apPOL and typical A-family 
members reside in signature motifs determined through sequence alignment. This work focuses 
on the composition of these signature motifs and other significant structurally differences we 
identified, as well as how these regions may impact polymerase activity and fidelity. The 
atypical elements described in this paper will assist in investigating the biochemistry of apPOL, 
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and will aid in the development of antimalarial drug compounds that are potent and specific to 
apPOL. 
Chapter four details with the development of a fluorescence-based assay that can be used 
to screen for inhibitors of apPOL in a high-throughput manner. The assay is based on a 
molecular beacon and is able to indirectly detect polymerase activity in a continuous manner. 
The assay is robust and has been validated for the National Institutes of Health’s requirements 
for a high-throughput screening assay. A pilot screen demonstrated that the assay can be used to 
screen large libraries of small molecules and is able to identify apPOL inhibitors with a wide 
array of inhibitory mechanisms. The assay was further tested for its ability to be used to perform 
steady state kinetics in a low throughput manner. A known inhibitor of nucleic acid binding 
proteins was selected, and its mechanism for inhibiting apPOL was established. This work 
provides a solid platform for the high-throughput identification of apPOL inhibitors.  
Altogether, this work establishes the means for identifying compounds which target 
apPOL. Determining the structure of apPOL allows for further characterization of inhibitors, and 
the means for understanding the atypical nature of the apicoplast DNA polymerase. This work 
will allow for the optimization of lead antimalarial compounds through the coupling for target 
based drug discovery and structure-guided drug design. 
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CHAPTER 2 
CRYSTALLIZATION AND PRELIMINARY X-RAY ANALYSIS OF THE PLASMODIUM 
FALCIPARUM APICOPLAST DNA POLYMERASE 
Morgan E Milton, Jun-Yong Choe, Richard B Honzatko, and Scott W Nelson 
Modified from a paper published in Acta Crystallographica Section F (2015). F71, 333-337. 
Abstract 
Infection by the parasite Plasmodium falciparum is the leading cause of malaria in 
humans. The parasite has a unique and essential plastid-like organelle called the apicoplast. The 
apicoplast contains a genome that undergoes replication and repair through the action of a 
replicative polymerase (apPOL). apPOL has no direct orthologs to mammalian polymerases and 
is therefore an attractive anti-malarial drug target. No structural information exists for apPOL 
and the Klenow fragment of E. coli DNA polymerase I, which is its closest structural homolog, 
shares only 28% sequence identity. Here, we report conditions of crystallization and preliminary 
X-ray diffraction data from crystals of P. falciparum apPOL. Data complete to 3.5 Å resolution 
were collected from a single crystal (2 x 2 x 5 µm) using a 5 µm beam. The space group P6522 
(unit cell a = b = 141.8 Å, c = 149.7 Å, α = β = 90° and γ =120°) was confirmed by molecular 
replacement. Refinement is in progress. 
Introduction 
Almost half of the world’s population is at risk of malaria. In 2012, there were 
approximately 207,000,000 cases worldwide, resulting in 627,000 deaths (1). The cause of 
malaria is a group of parasites from the genus Plasmodium, with the most common being P. 
falciparum and P. vivax. Drug resistance has been a constant problem and the spread of drug-
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resistant parasites in central Africa, India, southeast Asia, and northern South America has left 
common antimalarial drugs such as chloroquine, artemisinin, and sulfadoxin–pyrimethamine 
ineffective (2). 
Plasmodium spp. are members of the phylum Apicomplexa, which is composed 
exclusively of unicellular protozoan parasites and contains several other important human and 
animal pathogens such as Toxoplasma gondii (toxoplasmosis), Babesia bovis (babesiosis), 
Cyclospora cayetanensis (cyclosporiasis), and Eimeria falciformis (coccidiosis). All of these 
organisms contain a unique organelle called the apicoplast that has been shown to be essential 
for the survival of the parasites within their host. The apicoplast arose through a secondary 
endosymbiosis event with red algae and can be viewed as an ancient chloroplast (3). While it has 
not maintained the photosynthetic abilities of its parent organelle, the apicoplast is responsible 
for the execution of several biochemical processes such as the synthesis of isoprenoids, fatty 
acids, and hemes, along with iron–sulfur cluster maturation (4). 
Like the mitochondria and chloroplast, the apicoplast houses its own genome that must 
undergo replication and repair, but its genome lacks genes coding for enzymes involved in DNA 
replication (5). In 2004, the prex (plastidic DNA replication/repair enzyme complex) gene was 
identified. Prex encodes the putative apicoplast DNA primase, helicase and polymerase in the 
form of a polyprotein that has an N-terminal sequence targeting it to the apicoplast. Following 
import, Prex is cleaved by an unknown protease into three separate proteins (6). The P. 
falciparum apicoplast DNA polymerase (apPOL) is the only known DNA polymerase targeted to 
the apicoplast, and we have previously demonstrated that the activity and fidelity of apPOL is 
consistent with that of a replicative DNA polymerase (7). 
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Owing to the essential nature of the apicoplast in malaria parasites, apPOL is an 
especially attractive target for the development of antimalarial drugs. Bioinformatics studies 
indicate that apPOL is of prokaryotic origin and is a member of the A-type family of DNA 
polymerases (8). A-family DNA polymerases fall into five main groups: typical bacterial PolAs, 
thermophilic viruses, Aquificaceae/Hydrogenothermaceae, Apicomplexa, and other unrelated 
bacteria. While many members of the typical A-family DNA polymerases (for example, 
Escherichia coli PolI, Taq polymerase, and mitochondrial DNA polymerase γ) have been 
extensively studied at a biochemical and structural level, very little is known regarding the 
polymerases from the other four distinct A-family clades. P. falciparum apPOL shares only 28% 
sequence identity with the Klenow fragment of E. coli PolI (PDB 2KFN, 9), which is its closest 
structurally characterized homolog (10). On the other hand, the identity between different 
apPOLs is relatively high (84% identity between P. falciparum and P. vivax, the two primary 
agents of human malaria). This suggests that drugs designed to target apPOL from P. falciparum 
would be effective in treating malaria caused by other Plasmodium species. Here, we report the 
expression, purification, crystallization, and preliminary X-ray analysis of apPOL. The 
apicoplast DNA polymerase sequence is highly conserved among members of the Plasmodium 
genus and the structural information gathered through this study will aid in the discovery and 
development of antimalarial drugs. 
Materials and Methods 
Protein preparation 
The pET-28b vector (Novagen) containing apPOL (P. falciparum Prex residues 1389–
2016) was used to generate a 3ʹ-to-5ʹ exonuclease-deficient mutant apPOLexo− (D1470N and 
E1470Q) as described previously (7, Table 1). The resulting vector was transformed into E. coli 
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BL21(DE3) cells (Novagen), 
which were grown in LB 
medium at 310 K to an optical 
density of 0.7 at 600 nm. 
Isopropyl β-D-1-
thiogalactopyranoside (IPTG) 
was added to a concentration of 
0.2 mM to induce translation. 
The induced cultures were 
grown overnight at 291 K. The 
cells were harvested by 
centrifugation for 20 min at 
3000g and 277 K, suspended in 
a minimal volume of 20 mM Tris-HCl pH 8.0, 500 mM NaCl, 5 mM imidazole (buffer 1), and 
stored at 193 K. The polymerase was purified at 277 K as described by Miller et al. (11). The 
lysate from homogenized cells (EmulsiFlex-C5) was centrifuged for 1 h at 30,000g and 277 K. 
The supernatant was loaded onto a 5 ml Ni-agarose column and washed with buffer 1 and then 
with 20 mM Tris-HCl pH 8.0, 1 M NaCl, 25 mM imidazole. 1 M NaCl removes nucleic acids 
from the immobilized polymerase. 20 mM Tris-HCl pH 8.0, 500 mM NaCl, 150 mM imidazole 
was used to elute the polymerase. The eluted apPOLexo− was concentrated to 10 mg ml-1 as 
determined spectrophotometrically using an extinction coefficient ε280 of 56750 M-1 cm-1. The 
sample was then subjected to size-exclusion chromatography using a 320 ml HiLoad 26/200 
Superdex 200 column (GE Healthcare Biosciences) equilibrated with 20 mM Tris-HCl pH 8.0, 
Macromolecule-production information.
Source organism P. falciparum
DNA source GenScript
Forward primer† 5ʹ-GGTGGTCATATGGATGAAATCACCAAAAAATAA-
ATCACCAAAAAATACATCAAAG-3ʹ
Reverse primer‡ 5ʹ-GGTGGTGGATCCTTAATCTTTGCTACCCCAGTC-
TTTGCTACCCCAG-3ʹ
Exonuclease mutation primer  5ʹ-GATATTAAATATTGCGGCCTGAATATCCAAAA-
CCAGGGGTCTGGAAGTG-3ʹ
Expression vector pET-28b
Expression host  E. coli  BL21(DE3)
Complete amino-acid sequence 
of the construct produced
MGSSHHHHHHSSGLVPRGSHDEITKKYIKDNIINVDDNI
IKKKDIFKLKNENNEITECAFEYFESKKKFDDDIESRFF
IINDNNYNENINLIYKDIKYCGLDIETTGLEVFDENIRL
IQIAVENYPVIIYDMFNINKKDILDGLRKVLENKNIIKI
IQNGKFDAKFLLHNNFKIENIFDTYIASKLLDKNKNMYG
FKLNNIVEKYLNVILDKQQQNSVWNNSLLNNNQLFYAAR
DSSCLLKLYKKLKEEIKKENLHIVNDIENKCILPICDME
LNGIKVDLENLQKSTNEILNELNIEKDNLKKKLKDENIN
VNSQQQVLKALQKNNVRDISNKLIENTSDSNLKNFLNHE
EIISLRNYRRLYKLYSAFYLKLPLHINTKTNKIHTTFNQ
LKTFSGRFSSEKPNLQQIPRQKNIREIFIPNDNNIFIIA
DFKQIELKIAAEITNDEIMLKAYNNNIDLHTLTASIITK
KNIPDINKEDRHIAKAINFGLIYGMNYVNLKNYANTYYG
LNMSLDQCLYFYNSFFEHYKGIYKWHNQVKQKRALQYST
LSNRKVIFPYFSFTKALNYPVQGTCADILKLALVDLYDN
LKDINGKIILCVHDEIIIEVNKKFQEEALKILVQSMENS
ASYFLKKVKCEVSVKIAENWGSKD
† The NdeI site is underlined.     ‡ The BamHI site is underlined.
Table 1 
32 
400 mM NaCl. Fractions containing apPOLexo− were pooled and concentrated to approximately 
15 mg ml-1 using 50,000 NMWL Amicon Ultra-15 Centrifugal Filter Devices (Merck Millipore). 
High salt (400 mM) was used throughout the purification and crystallization process to ensure 
the stability of apPOL, which precipitates after prolonged periods (approximately 2 d) at lower 
salt concentrations. Protein purity was evaluated at each step by SDS–PAGE using Coomassie 
Blue stain. Control reactions indicated that our preparations were free of nuclease and 
phosphatase activity which would possibly interfere with polymerization assays. Polymerase 
activity was confirmed using methods described previously (11). Aliquots of purified apPOLexo− 
were flash-frozen in liquid nitrogen and stored at 193 K. The freezing process does not impact on 
the polymerase activity or crystallization. Cells for the preparation of SeMet- apPOLexo− were 
grown in M9 minimal medium supplemented with 50 mg SeMet 15 min prior to induction with 
IPTG. Labeled polymerase was purified in an identical manner to unlabeled polymerase and 
resulted in a slightly depressed protein yield, with unaltered catalytic activity. 
Protein for crystallization was evaluated by multi-angle light scattering (MALS). The 
polymerase sample was passed through a 0.22 mm cellulose acetate Spin-X centrifuge tube filter 
(Electron Microscopy Sciences) prior to data collection. MALS data were collected by passing 
the elutant from a Superdex 200 10/300 GL column (GE Healthcare) equilibrated with 20 mM 
Tris-HCl pH 8.0, 400 mM NaCl into a DAWN HELEOS II light-scattering system and Optilab 
T-rEX refractive-index detector (Wyatt Technology). The data were analyzed with the ASTRA 
software package. 
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Crystallization and X-ray data collection 
Initial attempts employed Crystal Screen, Crystal Screen 2 and Index (Hampton 
Research) and vapor diffusion in 96-well sitting-drop plates. Promising outcomes were replicated 
and optimized by hanging-drop vapor-diffusion experiments. Polymerase (4–18 mg ml-1) in 
20mM Tris-HCl pH 8.0, 400 mM NaCl was combined with the well solutions in a 1:1 ratio to 
give a final droplet size of 4 ml (Table 2). Variation of the ratio of solutions and the drop size did 
not appear to affect the quality and the size of the crystals produced. The trays were equilibrated 
at room temperature. Prior to data collection, crystals were looped and immediately flash-cooled 
in liquid nitrogen. Diffraction data were collected at 100 K using a MAR300 CCD detector on 
Advanced Photon Source beamline 23-ID-B (GM/CA-CAT). At a crystal-to-detector distance of 
350 mm, 50 frames were collected 
using an oscillation range of 1° 
and a 5 mm mini-beam. Data 
were processed using HKL-3000 
(12). Additional analysis and 
molecular replacement was 
performed using PHENIX (13). 
Results and Discussion 
The yield of apPOLexo−, which was 98% pure according to ImageQ (GE Healthcare) 
analysis of a Coomassie Blue stained SDS–PAGE, was approximately 50 mg per liter of LB 
(Figure 1a). MALS data revealed a single peak corresponding to a molecular mass of 68.9 kDa 
(Figure 1b), which is in agreement with the gene-calculated mass of 73.9 kDa. Microcrystals 
Crystallization.
Method Vapor diffusion
Plate type Hanging drop
Temperature (K) 298
Protein concentration (mg ml-1) 4–18
Buffer composition of protein solution 20 mM Tris pH 8.0, 400 mM NaCl
Composition of reservoir solution 0.2 M ammonium sulfate, 0.1 M 
MES monohydrate pH 6.5, 30% 
(w/v ) PEG monomethyl ether 
Volume and ratio of drop 4 μl, 1:1 protein:well solution
Volume of reservoir (μl) 500
Table 2 
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grew within two weeks in droplets consisting of a 1:1 ratio of protein solution and well solution 
consisting of 0.2 M ammonium sulfate, 0.1 M MES monohydrate pH 6.5, 30% PEG monomethyl 
ether 5000 (Crystal Screen 2 condition No. 26). Crystals produced under this condition 
resembled short-grain rice, with approximate dimensions of 2 x 2 x 5 µm (Figure 2). Although 
crystallization was highly reproducible using the premade solution from Hampton Research 
(regardless of the production lot), in-house solutions failed to consistently generate crystals and 
SeMet-labeled protein did not produce crystals under this, seeding or any other conditions. 
A beam with a 20 µm cross-section provided 
diffraction from microcrystals to a resolution of only 8Å; 
however, a beam with a 5 µm cross-section decreased the 
background radiation without loss of signal, revealing 
intensities to a resolution of 2.8 Å in a single image 
resulting from an exposure time of 10 s (14). The crystals 
were radiation-sensitive, so the exposure time was limited 
Figure 1. (a) SDS–PAGE analysis following purification of apPOLexo−. Lane 1, pooled fractions after size-
exclusion chromatography. Lane 2, peak fraction from MALS. (b) SEC–MALS trace for apPOLexo− as 
monitored by absorbance at 280 nm (black). The calculated molecular mass was determined to be 68.9 kDa 
(grey). (c) Polymerase activity assay using the molecular beacon hairpin DNA substrate as previously 
described in Miller et al. (11) without dNTPs (grey) and with dNTPs (black). The assay was performed with 
50 nM DNA and 50 nM apPOLexo−. 
Figure 2. A typical apo apPOLexo− 
microcrystal with dimensions of 
approximately 2 x 2 x 5 µm. 
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to 2 s in order to collect complete data from a 
single crystal (at least 30 images). The crystal 
received an average radiation dose of 134.61 
MGy as calculated by RADDOSE-3D (15). 
This well exceeds the maximum dose of 30 
MGy recommended for macromolecular 
crystallography (16). Radiation damage was 
visually apparent over the 50 frames of data 
collected as the resolution decreased from just beyond 3.5 Å to approximately 4.5 Å. Also 
influencing the strategy for data collection was a frequency of one in 60 flash-cooled crystals 
that exhibited high-resolution ordered diffraction. The aforementioned circumstances resulted in 
complete data, but only to a resolution of 3.5 Å largely owing to the short exposure time of 2 s 
and radiation damage Figure 3a, Table 3). Data reduction initially assumed a trigonal lattice, but 
further analysis indicated space group P6122 (or its enantiomorph), with unit-cell parameters a = 
b = 141.8, c = 149.7 Å, α = β = 90, γ = 120°. The Matthews coefficient of 2.94 Å3 Da-1 is 
consistent with one polymerase molecule per asymmetric unit and a solvent content of 58.2%. 
Data were originally scaled with a resolution cutoff at 3.5 Å (Table 3). The inclusion of all 
available diffraction data resulted in qualitative improvement of the electron-density map, but the 
I/σ(I) values for each shell suggest that the nominal resolution of the data is 3.5 Å. 
Initial molecular replacement was performed using Phaser (17) and resulted in a 
translation-function Z-score (TFZ) of 4.4, a rotation-function Z-score (RFZ) of 3.1, and a log-
Data collection and processing.
Values in parentheses are for the outer shell.
Wavelength (Å 1.0332
Exposure time per image (s) 2
Space group P6522
Unit-cell parameters (Å, °) a = b = 141.8, c = 149.7,
α = β = 90, γ = 120
Resolution range (Å) 50.0–3.5 (3.63–3.50)
Total No. of reflections 11190 (1081)
Completeness (%) 95.4 (95.1)
Multiplicity 3.6 (3.5)
‹I /σ(I )› 4.9 (1.75)
Rmerge 0.151 (0.390)
Table 3 
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likelihood gain (LLG) of 49.555 
when an unmodified Klenow 
fragment (PDB 2KFN, 9) was 
used as the molecular-replacement 
model. Use of only the polymerase 
domain of the Klenow fragment 
(residues 519–928), which has 
31% sequence identity to 
apPOLexo− but alone only accounts 
for 63% of the total apPOLexo− 
molecule, resulted in a molecular-
replacement solution (electron 
density revealing right-handed α-
helices as shown in Figure 3b) 
only in space group P6522, with a 
TFZ of 6.2, an RFZ of 3.9, and an 
LLG of 63.248 (13). Subsequent 
use of MR-Rosetta (18) using the 
unmodified PDB 2KFN (complete 
with DNA and ions) as the model 
independently indicated the same 
space group and a partial model 
with approximately 450 of the 628 
Figure 3. (a) X-ray diffraction pattern of an apPOLexo− microcrystal 
produced from a 2 s exposure. The first image collected from a data 
set of 50 frames is shown. Weak diffraction extends to 2.8 Å 
resolution, with stronger diffraction extending to approximately 3.5 
Å resolution as shown by the black circle. (b) Density map and 
model from early refinement after molecular replacement. The 
density shows clear right-handed helices and crystal lattice contacts. 
Coordinates are shown in yellow and symmetry atoms are shown in 
pink. 
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expected residues placed in electron density. MR-Rosetta failed to model 67 residues at the N-
terminus which make up part of the apPOLexo− exonuclease domain. Over half of these residues 
are found exclusively in members of the Plasmodium genus and appear to be important in 
producing an active polymerase (7). Density is clearly present for these residues and a model is 
currently being manually built. 
Several circumstances were unfavorable for structure determination: radiation-sensitive 
microcrystals, most of which failed to diffract in an ordered manner, low sequence identity to 
known structures and failure to grow SeMet-derivative crystals. Nonetheless, the advanced 
capabilities of synchrotron facilities resulted in complete data and successful structure 
determination. Further development of the exonuclease domain will require manual building in 
regions of low or absent sequence identity. Preliminary work, however, clearly supports the 
thumb-palm-finger structure observed in other A-type polymerases. 
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CHAPTER 3 
CRYSTAL STRUCTURE OF THE APICOPLAST DNA POLYMERASE FROM 
PLASMODIUM FALCIPARUM: THE FIRST LOOK AT AN “ATYPICAL” A-FAMILY DNA 
POLYMERASE 
Morgan E Miller, Jun-Yong Choe, Richard B Honzatko, and Scott W Nelson 
Modified from a paper submitted for publication in PNAS Plus. 
Abstract 
Plasmodium falciparum, the primary cause of malaria, contains a non-photosynthetic 
plastid called the apicoplast. The apicoplast exists in most members of the phylum Apicomplexa 
and has its own genome along with organelle-specific enzymes for its replication. The only DNA 
polymerase in the apicoplast (apPOL) is an atypical A-family polymerase and here we present its 
crystal structure at a resolution of 2.9 Å. apPOL, the first structural representative of the atypical 
A-family, diverges from typical polymerases in two of three previously identified motifs and a 
region not implicated by sequence. Moreover, apPOL has an additional N-terminal subdomain, 
the absence of which severely diminishes 3ʹ to 5ʹ exonuclease activity. A compound known to be 
toxic to Plasmodium is a potent inhibitor of apPOL, suggesting apPOL is a viable drug target. 
The structure of apPOL will facilitate the mapping of inhibitors to binding loci and provide a 
basis for structurally-guided antimalarial drug design. 
Introduction 
The phylum Apicomplexa includes parasites responsible for malaria, toxoplasmosis, 
cyclosporiasis, and babesiosis. Malaria, caused by Plasmodium, is a mosquito-borne disease with 
200 million cases annually, resulting in almost 450,000 deaths (1). Half of the world’s 
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population is at risk of infection by Plasmodium falciparum, the most common and deadly cause 
of malaria. Malarial parasites in central Africa, India, southeast Asia, and northern South 
America are becoming resistant to common antimalarial drugs, such as chloroquine, sulfadoxin–
pyrimethamine, and artemisinin (2). Intense efforts to develop a malaria vaccine have provided 
only a single candidate that has progressed past Phase 3 clinical trials (3). Hence, the 
development of new and potent antimalarial treatments will likely play a central role in the 
eradication of malaria (1). 
Nearly all members of the phylum Apicomplexa have an essential organelle called the 
apicoplast. Genetic analysis supports the evolution of the apicoplast from the chloroplast of a red 
algae (4), presumably captured in an endosymbiotic event. The apicoplast has lost its 
photosynthetic capabilities, but maintains several biochemical processes within the parasite. 
Proteins involved in fatty acid biosynthesis, heme synthesis, Fe-S cluster maturation, and 
isoprenoid synthesis contain an apicoplast targeting sequence (5). In P. falciparum, the synthesis 
of isoprenoid precursors is an essential role of the apicoplast during the liver and blood stages of 
infection in humans (6). Drugs that disable the apicoplast may be potent treatments and 
chemoprotectants against malaria (7). 
As a consequence of gene transfer to the host cell nucleus, the genomes of endosymbiotic 
organelles are of reduced size relative to those of related free-living organisms (8). The 
apicoplast of P. falciparum contains a 35 kilobase (kb) circular genome with homology in genes 
and organization to plastid genomes of algae. Nearly all of the apicoplast genome is dedicated to 
gene expression, with no genes encoding for DNA replication proteins (9). Instead, the nuclear 
genome houses the prex gene (10), which is translated into a single polyprotein targeted to the 
apicoplast. Following translocation into the apicoplast, an unknown protease cleaves Prex into 
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separate and functional helicase, primase, and polymerase proteins (10). We have previously 
demonstrated that the polymerase derived from Prex (apPOL), the only known DNA polymerase 
targeted to the apicoplast, has activity and fidelity consistent with a replicative DNA polymerase 
(11). 
A-Family polymerases predominantly come from bacteria, mitochondria, and 
bacteriophage (12). Bacterial DNA polymerases often elongate Okazaki fragments, remove RNA 
primers during replication, and repair DNA. Such polymerases employ a 5ʹ to 3ʹ polymerase 
domain, a 3ʹ to 5ʹ exonuclease proofreading domain, and a 5ʹ to 3ʹ exonuclease domain for 
primer removal and DNA repair (11, 12). The Klenow fragment from Escherichia coli 
Polymerase I (Klenow), the large fragment of DNA polymerase from Bacillus 
stearothermophilus (BF), the DNA polymerase from bacteriophage T7 (T7), the DNA 
polymerase from Thermus aquaticus (Taq), and the mitochondrial DNA polymerase (polγ) 
comprise the known structures of the A-family. Each resembles a right hand with finger, palm, 
and thumb subdomains. The palm subdomain is well-conserved, whereas the finger and thumb 
subdomains are relatively divergent across species (13). The 3ʹ to 5ʹ exonuclease domains are 
poorly conserved except for three amino acid motifs at or near the exonuclease active site (14). 
Outside of Apicomplexa, the closest homolog to apPOL is from Cyanothece sp. PCC 8802 (35% 
sequence identity), putatively acquired through lateral gene transfer from a lysogenic phage (15). 
Klenow is the closest structural homolog of apPOL, sharing 28% sequence identity. 
A-family DNA polymerases divide into five clades: typical PolA bacteria, thermophilic 
viruses, Apicomplexa, Aquificaceae/Hydrogenothermaceae, and other unrelated bacteria (15). 
Typical A-family DNA polymerases have been well studied biochemically and structurally. 
Little is known, however, about the other four A-family clades, which have been deemed 
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atypical on the basis of three sequence motifs (14, 15). These signature motifs could represent 
distinct and unknown biochemical or physiological attributes, and indeed one lies in a region that 
could impact polymerase fidelity (15, 16). Bioinformatic studies classify apPOL as prokaryotic 
in origin and an atypical member of the A-family DNA polymerases (10). 
Detailed mechanisms of DNA polymerization for typical A-family members come from 
extensive studies of Klenow and BF (17–21). In contrast, atypical attributes of apPOL are largely 
hypothetical. Presented here is the crystal structure of P. falciparum apicoplast DNA 
polymerase, the first structure of an atypical A-family polymerase. The crystal structure defines 
atypical elements and suggests mutations that probe function. Moreover, several distinguishing 
features of apPOL may afford selective inhibition and facilitate the development of new anti-
malarial therapies. 
Materials and Methods 
Protein Preparation 
All protein constructs were purified as described (22). Mutagenesis was performed using 
QuickChange mutagenesis to generate exonuclease deficient mutants (D82N and E84Q), 
catalytic base mutants (H578Q), and finger tyrosine mutants (Y481A/485A/Y486A). 
Crystallization and data collection 
Crystallization experiments employed the method of hanging drops. N-apPOLexo− 
produced microcrystals (22) by the combination of equal parts protein solution (4–16 mg ml−1 N-
apPOLexo−, 20 mM Tris-HCl pH 8.0, and 400 mM NaCl) and precipitant solution (0.2 M 
ammonium sulfate, 0.1 M MES monohydrate pH 6.5, and 35% w/v polyethylene glycol 
monomethyl ether 5,000). We flash froze crystals in liquid nitrogen without additional 
cryoprotectant. We collected X-ray diffraction data at the Advanced Photon Source beamline 23-
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ID-B (GM/CA) at 100 K and wavelength 1.0332 Å. We recorded 50 images from a single N-
apPOLexo− crystal (physical dimensions of 2×2×5 µm) using a MAR300 CCD detector, crystal-
to-detector distance of 350 mm, an exposure time of 2.0 s, oscillation of 1°, and beam size of 5 
µm. 
Crystals of C-apPOLexo− appeared after the structure determination of the N-apPOLexo− 
crystal form. C-apPOLexo‒ crystallized from equal parts protein solution (10–15 mg/ml C-
apPOLexo−, 0.2 M magnesium acetate tetrahydrate, and 0.1 M sodium cacodylate trihydrate pH 
6.5) and precipitant solution (20% w/v polyethylene glycol 8,000). We collected X-ray 
diffraction data at the Advanced Photon Source beamline 23-ID-B (GM/CA) at 100 K and 
wavelength 1.0332 Å. We recorded 360 images from a single crystal (10×10×100 µm) using a 
MAR300 CCD detector crystal-to-detector distance of 350 mm, an exposure time of 2.0 s, 
oscillation of 1°, and beam size of 10 µm. 
Data processing 
We processed data from the N-apPOLexo− crystal using HKL-2000 (23) by two 
approaches: a sigma cutoff of zero, which excluded all negative intensities, and a sigma cutoff of 
−1.0, which eliminated large-negative but retained weak-negative intensities. In subsequent 
refinements, the two data sets provided virtually identical values for R-work, R-free, average B, 
and parameters of stereochemistry. However, the completeness of the data set in the last shell 
(2.9–3.0 Å) was 96.4% and 58.2%, for sigma cutoffs of −1.0 and zero, respectively. The model 
and associated data deposited in the PDB results from refinement using the more complete data 
set (overall Rsym of 0.345) instead of the negative-purged data set (overall Rsym of 0.178). 
Statistical analysis of intensities indicated a 100% probability for the space groups P6522 or 
P6122 for crystals of N-apPOLexo−. 
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Data reduction included only the first 60 images (overall Rsym of 0.094) from the crystal 
of C-apPOLexo‒ in order to eliminate the impact of radiation damage. Statistical analysis of 
intensities indicated a 99% probability for the space group P65 or P61 for crystals of C-
apPOLexo−. 
Structure determination and refinement 
The first crystals to appear were those of N-apPOLexo‒. These presented a challenge 
related to crystal size (< 5 μm), limited lifetime in the X-ray beam (< 120 s), modest resolution 
of diffraction, and low sequence identity (28%) to the closest available structure, Klenow (PDB 
2KFN). Regardless, the polymerase domain of Klenow led to an initial molecular replacement 
solution of the crystal structure of N-apPOLexo‒. Electron density recognizable as α-helices 
appeared only in the space group P6522. Subsequent molecular replacement and automated 
model building employed MR-Rosetta (24) and Klenow (PDB 2KFN). Operational parameters of 
MR-Rosetta were those of Terwilliger et al. (25), except 3 models rather than 100 were built 
during each round of MR-Rosetta to reduce computational time. Two cycles of MR-Rosetta 
resulted in a model with approximately 450 of 628 expected residues. We built an additional 125 
residues manually using Coot (26) in regions between elements of secondary structure and in 
regions for which no structural analog existed (first 67 residues of apPOL). Refinement with 
Phenix.refine (27) along with user-specified donor-acceptor restraints aided in the correct 
registration of the amino-acid sequence to the electron density by enforcing canonical hydrogen-
bonding patterns. Donor-acceptor restraints involved main-chain atoms initially, then all 
combinations of main-chain and side-chain atoms were imposed with target distances of 2.86 ± 
0.1 Å. We did not use donor-acceptor restraints for residues preceding and following prolines in 
α-helices. We assigned significant difference density in the exonuclease and active site to two 
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molecules of ammonium sulfate (concentration of approximately 200 mM in crystallization 
droplets) and a partially hydrated Na+ (concentration of approximately 400 mM in droplets). We 
restrained coordination distances to Na+ involving the oxygen atoms of water molecules and a 
protein side-chain to 2.5 ± 0.01 Å. We placed seven ammonium sulfate molecules in the 
polymerase active site and at a lattice contact. In the late stages of refinement, we removed 
donor-acceptor restraints if refined distances exceeded 3.26 Å (4-sigma threshold), or if 
difference density clearly indicated that restraints restricted optimal placement of main- and/or 
side-chain atoms. Restraints on donor-acceptor distances maintained canonical secondary 
structure, favorable rotamer angles (0.2% unfavorable) and allowed conformations (99.3%) by 
Ramachandran analysis. The inclusion of hydrogen atoms using the Phenix routine ReadySet!, 
reduced clashscores from ~10 to 1.23 and resulted in an overall score out of MolProbity (28) of 
1.38. 
Molecular replacement determination of the C-apPOLexo− crystal form employed the 
model for N-apPOLexo−. Unit cell parameters for the C-apPOLexo‒ crystal form indicated two 
polymerase molecules in the asymmetric unit. We used the program Phaser (29) in the Phenix 
suite in placing the first polymerase molecule (TFZ > 8), identifying the space group as P65. A 
second run of Phaser with fixed coordinates for the first molecule resulted in the complete 
molecular replacement solution (TFZ > 16). We refined donor-acceptor restraints, but only 
between main-chain atoms. We placed an octahedrally coordinated Mg2+ (approximate 
concentration of 200 mM in the crystallization droplet) at the exonuclease active site, with the 
oxygen atoms of five water molecules and a protein side chain restrained to a distance of 2.10 ± 
0.01 Å. We added hydrogen atoms with the program ReadySet!. The refined model has 99.5% of 
residues in allowed/favorable Ramachandran conformations, 0.9% residues with unfavorable 
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rotamer angles, a clashscore of 0.77, and a score out of MolProbity of 1.07. We generated figures 
using PyMOL (http://www.pymol.org/) and VMD (http://www.ks.uiuc.edu/Research/vmd/) and 
calculated the electrostatic surface with PBEQ Solver (30). 
Pre-steady state polymerase activity assay 
Oligonucleotide template (5ʹ–TTTTTTCACTAGCTGACTGACACCTG) and primer (5ʹ–
HEX-CAGGTGTCAGTCAGCTAGTG) were obtained from Integrated DNA Technologies. 
Reactions occurred at 25°C in 20 mM Tris-HCl pH 8.0, 10 mM magnesium acetate, 50 mM 
potassium acetate, 1 mM DTT, and 0.1 mg ml−1 BSA with 200 µM dATP, 4 µM apPOL, and 400 
nM annealed duplex DNA. Reactions were quenched with 100 mM EDTA. Time points less than 
5 s were performed on a Biologic QFM-400. Data was visualized on a 16% denaturing 
acrylamide gel containing 7.5 M urea in Tris-borate-EDTA (TBE) buffer. Gels were scanned on 
a Typhoon FLA9500 (GE Healthcare). Data was analyzed using ImageQuant TL (GE 
Healthcare) and apparent kpol values were determined by data fitting to a single exponential 
equation, P=P0+P∞(1-e-kpolt), in SigmaPlot. Assays were performed in triplicate. 
 
DNA-binding determination 
Oligonucleotide template (5ʹ–TTTTTTCACTAGCTGACTGACACCTG) and primer (5ʹ–
CAGGTGTCAGTCAGCTAGTG) were obtained from the Iowa State University DNA Facility. 
The primer was radioactively labeled with 32P using T4-polynucleotide kinase (New England 
Biolabs). Reactions were carried out in the same buffer as above with 20 nM final duplex DNA 
and 0–2 µM apPOL. A 96-well Bio-Dot (Bio-Rad) was assembled with 0.45 µm nitrocellulose 
membrane (Bio-Rad), 0.45 µm positively charged nylon transfer membrane (GE Water + 
Process Technologies), and Whatman filter paper (Fisher Scientific). Membranes were washed 
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three times with 100 µL of reaction buffer prior to loading 100 µL of sample and three more 
washes with 100 µL each of reaction buffer. Membranes were visualized using a Typhoon 
FLA9500 and analyzed using ImageJ (National Institutes of Health, Bethesda, MD). The kd was 
determined using DYANFIT (31) and experiments were performed three times with two 
replicates each. 
Apparent-Km and Vmax determination 
Parameters of steady state kinetics (apparent-Km for nucleoside triphosphates and Vmax) 
for N-apPOLexo- and N-apPOLexo‒/Y481A/Y485A/Y486A were determined using the DNA hairpin 
substrate containing the Cy3 and BQ1 dye/quencher pair as described previously (32). Reactions 
were carried out at 25 °C in 20 mM Tris-HCl pH 8.0, 10 mM MgAc, 50 mM KAc, 1 mM DTT, 
0.1 mg/ml BSA, and 2% DMSO with 50 nM hairpin DNA, 10 nM polymerase, and nucleotide 
concentration varying from 0 to 4 µM. All data were collected on a Cary Eclipse Fluorescence 
Spectrophotometer using the Cary Kinetics software at an excitation wavelength of 545 nm and 
emission wavelength of 570 nm. Initial rates were analyzed using SigmaPlot software and the 
Michaelis-Menten equation. Assays were performed in triplicate. 
Exonuclease activity assay 
Oligonucleotide template (5ʹ–TTTTTTCACTAGCTGACTGACACCTG) and primer (5ʹ–
HEX-CAGGTGTCAGTCAGCTAGTG) were obtained from Integrated DNA Technologies. 
Reactions occurred at 37°C in 20 mM Tris-HCl pH 8.0, 10 mM magnesium acetate, 50 mM 
potassium acetate, 1 mM DTT, and 0.1 mg ml−1 BSA with 250 nM apPOL and 100 nM annealed 
duplex DNA. Reactions were quenched with 100 mM EDTA. Data was visualized on a 16% 
denaturing acrylamide gel containing 7.5 M urea in Tris-borate-EDTA (TBE) buffer. Gels were 
scanned on a Typhoon FLA9500 (GE Healthcare). Data was analyzed using ImageQuant TL (GE 
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Healthcare) and apparent kexo values were determined by data fitting in SigmaPlot fit to 
P=P0+P∞(1-e-kpolt). Assays were performed in triplicate. 
Results and Discussion 
Overview of apPOL structure 
Structural work employed an exonuclease-deficient mutant of apPOL (D82N/E84Q) with 
either an N-terminal hexahistidine tag (N-apPOLexo−) or a C-terminal tag (C-apPOLexo−). Crystals 
of N-apPOLexo− provided data to a nominal resolution (I/σI = 2) of 3.7 Å (22). MR-Rosetta (24) 
with Klenow [PDB 2KFN 
(33)] as a starting model 
provided a molecular 
replacement solution. The 
model output by MR-Rosetta 
had 450 of the expected 628 
residues of N-apPOLexo−. We 
manually built an additional 
125 residues between 
elements of secondary 
structure and in a region for 
which no structural analog 
existed (the first 67 residues 
of apPOL). Inclusion of data 
from 2.9-3.7 Å improved the 
interpretability of electron 
N-apPOLexo− (5DKT) C-apPOLexo− (5DKU)
Data collection
Space group P6522 P65
Cell dimensions  
    a , b , c  (Å) 141.78, 141.78, 148.76 146.38, 146.38, 165.67
    α, β, γ  (°) 90, 90, 120 90, 90, 120
Resolution (Å) 47.36-2.90 (3.00-2.90)a 47.90-2.90 (3.00-2.90)
R sym 0.345 (over 1)* 0.094 (0.526)
I / σI 3.4 (0.8) 14.9 (2.2)
Completeness (%) 97.8 (96.4) 99.3 (98.6)
Redundancy 4.2 (3.4) 3.5 (3.2)
Refinement
Resolution (Å) 47.34-2.90 47.91-2.90
No. reflections 19696 44,271
R work / R free 0.27/0.30 0.19 / 0.23
No. atoms
    Protein 4,800 9,665
    Ligand/ion 46 2
    Water 63 96
B -factors (Å2)
    Protein 48.6 65.5
    Ligand/ion 38.1 63.2
    Water 20 33
R.m.s. deviations
    Bond lengths 
(Å) 0.003 0.002
    Bond angles (°) 0.548 0.477
aValues in parenthesis correspond to the highest-resolution shell.
*See methods for comments on Rsym.
Table 1. Data collection and refinement statistics
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density maps. Auxiliary donor-acceptor restraints maintained the canonical secondary structure 
and increased the number of residues in allowed/favorable regions of the Ramachandran plot. 
The inclusion of hydrogen atoms in refinement reduced unfavorable interatomic contacts by one 
order of magnitude (clashscore decreased from 10 to 1). The polymerase model developed from 
the N-apPOLexo− crystal form (PDB 5DKT) was the basis for a structure determination by 
molecular replacement of the C-apPOLexo− crystal form (PDB 5DKU), resulting in a nominal 
Figure 1. Structure of the P. falciparum apicoplast DNA polymerase. The polymerase domain of apPOLexo− with 
finger (orange), thumb (purple), and palm (blue) subdomains. An N-terminal region (NTR, gray) extends the 
exonuclease domain (green). The polymerase and exonuclease active sites are marked by green spheres. Selected 
elements of secondary structure are labeled with all elements defined in Figure 8. 
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resolution of 2.9 Å. Auxiliary donor-acceptor restraints maintained canonical secondary 
structure, and the inclusion of hydrogen atoms reduced unfavorable interatomic contacts. Models 
of the polymerase, a total of three independent polypeptide chains over two crystal forms, exhibit 
only small conformational differences primarily in regions of lattice contact. Statistics of data 
collection and refinement are in Table 1. 
Much of apPOL (Figure 1 and Figure 3) structurally resembles typical members of the A-
family. The polymerase domain of apPOL shares finger, thumb, and palm subdomains of A-
family polymerases. The palm subdomain is structurally conserved (Figure 3) and includes 
residues responsible for the coordination of active-site metals involved in DNA primer extension 
(34). The finger subdomain plays a role in binding template DNA and incoming nucleoside 
triphosphate (35). Helix O of the finger subdomain adopts an “open” conformation as defined by 
the corresponding helix of BF in its open [PDB 1L3S (18)] and closed conformation [PDB 2HVI 
(36)] (Figure 2). The thumb subdomain positions and translocates the growing duplex DNA and  
Figure 2. Polymerase “open” and “closed” conformations. Helix N and Helix O of apPOL (blue) align with 
those of the open BF structure (cyan, PDB 1L3S) rather than those of the closed BF structure (pink, PDB 
2HVI). 
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may play a role in processivity. Approximately 50 residues between Helix H and Helix I of the 
thumb subdomain of apPOL are not modelled due to weak electron density. In other A-family 
polymerases, the corresponding region has either high thermal parameters or weak electron 
density not represented by a model. However, in primer/template complexes, conserved residues 
in this region interact with the DNA backbone (13).  
Even though exonuclease domains of A-family DNA polymerases vary broadly in 
sequence and secondary structure (14), active site residues are well-conserved in proofreading 
polymerases (19). apPOL has residues corresponding in position and type to polymerases with 
proofreading activity (details below). Nonetheless, a contiguous region of the apPOL 
exonuclease domain structurally diverges from the typical A-family polymerase  
Figure 3. (a) Multiple structural alignment (MSA) was generated in VMD using STAMP and Cα atoms. Color 
key runs from exact agreement in position and local conformation of corresponding Cα atoms (darkest blue, 
Qres = 1) to the presence of structure in apPOL not observed in the other structures (darkest red, Qres = 0). (b) 
Identical residues (orange) revealed in the alignment of A-family structures mapped onto the structure of 
apPOL (gray). (c) Alignment of sequences based on MSA of A-family polymerases. Residues 283-337 are 
absent from the model of apPOL and are not represented in the alignment. Conserved residues are highlighted 
orange, and key residues denoted by a star. Secondary structure is that of apPOL, color coded by subdomain as 
depicted in Figure 6. 
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(Figure 3). The N-terminal region (NTR), elements of the exonuclease domain juxtaposed to the 
NTR, and residues 170–206 spanning between the NTR and palm subdomain exhibit structural 
variations. Residues 170–192 include lysine residues which extend the electropositive surface 
charge from the polymerase active site to the exonuclease active site (see section on DNA-
polymerase models), residues 193–199 cover the exonuclease active site, and residues 204–206 
interact with the NTR. 
Polymerase and exonuclease active sites 
DNA polymerization putatively employs a two-metal-ion mechanism of nucleotidyl 
transfer (37) (Figure 4a, b).  Asp410, Asp579, and Glu580 in apPOL correspond to conserved 
residues that bind Mg2+ at sites A and B. The site B magnesium ion accompanies the binding of 
nucleoside triphosphate (16, 38). The magnesium ion at site A coordinates the 3ʹ-hydroxyl group 
of the DNA primer (39). No metals are present in the polymerase active sites of either N-
apPOLexo− (PDB 5DKT) or C-apPOLexo− (PDB 5DKU). The side chains of Asp579 and Glu580 
do not adopt χ1 rotamers consistent with those in metal-bound compl exes, instead hydrogen 
bonding with other active site residues (Figure 4c). Asp579 interacts with a conserved Arg377, 
whereas Glu580 interacts with Trp624 and/or Arg395. Metal-coordinating side chains of human 
Polβ, an X-family DNA polymerase (40), and A-family structures which lack DNA, exhibit 
similar salt links with arginyl side chains. In computational simulations of Pol β, the breaking of 
the salt link corresponding to apPOL Asp579-Arg377 is a significant energy barrier between the 
open and closed states (41). Consistent with this analysis, mutation of the arginine residue in Pol 
β results in a 2.5-fold enhancement in open-to-closed transitions (42). The rate-limiting step of 
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the polymerase reaction may be the change that brings about the closed conformation required 
for catalysis. This conformational change may be a checkpoint for correct nucleotide insertion. 
A conserved Helix O lysine (Lys463 in apPOL Figure 4a,b) likely serves as a general 
acid for all classes of polymerases, protonating the pyrophosphate leaving group (43). A catalytic 
base is not firmly established, as several functional groups are close to the proton of the 3ʹ-
hydroxyl group of the DNA primer. Mounting evidence, however, weighs in favor of a highly 
conserved histidine (His578 in apPOL) as the proton acceptor. Mutation of this histidine 
(His881) to alanine in Klenow causes a 10-fold decrease in activity (44). In molecular dynamic 
simulations, the corresponding histidine in BF, which crystallizes in a constrained conformation, 
undergoes a rapid conformational change to hydrogen bond with the 3ʹ-hydroxyl group of the 
primer (45). Mutation of His578 in apPOL to glutamine reduces catalytic activity by 100-fold 
(Figure 4d). apPOLexo‒ has a pre-steady state nucleotide incorporation rate (apparent-kpol) of 22 ± 
3 s‒1, whereas apPOLexo‒/H578Q has an apparent-kpol of 0.21 ± 0.02 s‒1. Sequence conservation, 
structural proximity, computational modeling, and biochemical studies together implicate His578 
as the probable proton acceptor from the 3ʹ-hydroxyl group in the polymerase reaction of apPOL. 
The exonuclease reaction putatively involves a pair of divalent metal ions which 
coordinate the phosphodiester backbone of DNA (46) (Figure 4e). In apPOL, three aspartate 
residues (82, 143, and 215) and a glutamate residue 84 probably coordinate metal ions. The 
mutation of Asp82 and Glu84 to corresponding amides likely reduces affinity for metal ions; 
nonetheless, Mg2+ and Na+ are present in the exonuclease active sites of C-apPOLexo− and N-
apPOLexo−, respectively. The N-apPOLexo− structure contains two sulfate anions roughly 8.5 Å 
apart that map to phosphoryl groups of DNA in the model of a DNA editing complex (described 
below). Conserved Tyr211 in apPOL may orient a metal-ligated hydroxide anion in the  
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Figure 4. Active Site Residues. (a) Alignment of active site residues of apPOL (blue), Klenow [gray, PDB 
1KLN (17)], BF (cyan, PDB 1L3S), and Taq [green, PDB 1TAQ (29)] modeled with the nucleoside 
triphosphate and site B magnesium ion from Taq [PDB 2KTQ (26)]. (b) Schematic of polymerase active site 
with the 3ʹ-end of the DNA primer (green), nucleoside triphosphate (blue), and divalent cations (red). Dashed 
lines represent donor-acceptor interactions and coordinate bonds. (c) Conserved residues Asp579 and Glu580 
in apPOL (blue) hydrogen bond with side-chains of arginine residues, whereas in the open DNA-BF complex 
(cyan, PDB 1L3S) the corresponding interactions do not occur. (d) Pre-steady state polymerase kinetics of 
apPOLexo− (blue) and apPOLexo−/H578Q (red). (e) The exonuclease active site of apPOL from PDB 5DKT with 
magnesium ion (green), and yellow spheres mark the positions of sulfate anions from PDB 5DKU. (f) 
Schematic of the exonuclease active site showing the 3ʹ-end of the DNA primer (blue) and divalent cations 
(red). 
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exonuclease reaction (46). However, its side chain is rotated away from the active site in N-
apPOLexo−. In C-apPOLexo− (sulfate anions absent), Tyr211 is directed into the active site, 
consistent with a role in catalysis. In addition to the aforementioned residues, two leucine 
residues (128 and 222, buried in separate locations of the domain core) and an aspartate residue 
159 are conserved (Figure 3). Asp159 hydrogen bonds with the backbone amides of residues 139 
and 140, orienting the main-chain carbonyls toward the metal binding sites of the exonuclease 
active site. This residue is present even in polymerases Taq and BF, which lack signature 
residues for exonuclease activity. 
DNA binding in the polymerase and exonuclease active sites 
Polymerase active sites have electropositive pockets which balance the negative charge 
of the phosphodiester backbone of DNA (47). apPOL exhibits the characteristic electropositive 
surface at the polymerase active site (Figure 5). For Klenow, BF, Taq, and T7, the polymerase 
active site electropositive region closely follows the template DNA strand, tapers off near the 
finger subdomain, and vanishes short of the exonuclease site Figure 5b). In contrast, apPOL has 
a continuous lysine-rich electropositive surface running from the polymerase active site to the 
exonuclease site, along with an electropositive band that wraps around the finger subdomain and 
extends down the side of the protein (Figure 5a).  
The DNA complex of BF polymerase (PDB 1L3S) is perhaps the most definitive 
representation of catalytically productive polymerase-DNA interactions, as it can extend a DNA 
primer within the crystal. The polymerase domain of BF shares only 25% sequence identity with 
apPOL, yet superimposes with a root mean squared deviation (rmsd) of 1.9 Å based on Cα 
atoms, placing the DNA primer/template into a region of electropositive charge with favorable 
contacts between DNA and the polymerase domain (Figure 5a). A nucleotide base from the  
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Figure 5. Surface charge of A-family polymerases. (a) The electropositive surface (blue) of apPOL extends well 
beyond the polymerase active site. (b) The electropositive surface (blue) of the DNA-BF complex (PDB 1L3S) 
maps to bound DNA (green), but is electronegative (red) in the region corresponding to the extended electropositive 
surface of apPOL. 
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template occupies the template pre-insertion site created from a slot between Helix O and Helix 
O1 (18) (Figure 6a, blowout). Residues that bind directly to DNA in the BF-DNA complex 
(Lys582, Ser585, Lys593, Arg615, Asn622, and Asn625) correspond to residues in apPOL of 
identical or similar type (Lys344, Ser347, Lys357, Arg377, Asn384, and Gln387, respectively). 
Lys372 and Lys382 of apPOL are proximal to the phosphodiester backbone of the DNA duplex 
and contribute to an electropositive surface that extends toward the exonuclease site. Tyr714 in 
open (PDB 1L3S) and in closed (PDB 2HVI) BF-DNA complexes exhibits a substantial 
displacement. In the open complex, Tyr714 blocks the template from access to its site for base 
insertion opposite that of the incoming nucleoside triphosphate, whereas in the closed complex 
the insertion site for the template base is accessible. Tyr714 is part of Helix O, the movement of 
which defines the open and closed conformations of BF. Other helices of the finger subdomain 
of BF with or without DNA superimpose well, as do the helices of Klenow (DNA absent). In the 
“open” apPOL structure, however, Tyr471 coincides with Tyr714 in its closed and unblocked 
BF-DNA complex. Moreover, helices of the finger subdomain of BF and Klenow exhibit 
substantial displacements relative to those of apPOL (Figure 6a). As these displacements remain 
in the superposition of apPOL onto Klenow and BF lacking DNA, the conformational 
differences are not necessarily due to the binding of DNA. Instead the helix displacements could 
be a consequence of sequence and structural differences in Helix Q and Helix P (described 
below). 
The crystal structure of Klenow (PDB 1KLN) putatively reveals DNA bound in the 
proofreading mode. Superposition of that complex onto apPOL (rmsd of 2.4 Å based on Cα 
atoms) docks the DNA primer strand into the apPOL exonuclease site (Figure 6b). The 
phosphodiester backbone of the DNA primer tracks along the extended electropositive surface  
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Figure 6. Modeled DNA-apPOL complexes. (a) DNA (template strand yellow, primer strand orange) from BF (PDB 
1L3S) modeled by superposition onto PDB 5DKT. Blow out shows interactions of the 5ʹ-template overhang (yellow) 
in two orientations with BF (cyan) aligned to apPOL (blue). (b) DNA (template strand yellow, primer strand orange) 
from Klenow (PDB 1KLN) transformed onto apPOL (blue) by the superposition onto apPOL with active site 
magnesium ion (green sphere). 
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that leads from the polymerase active site into the exonuclease active site (Figure 4a). Residues 
in Klenow that interact directly with the primer strand correspond to apPOL Asp/Asn82, 
Glu/Gln84, Leu88, Asp143, Tyr211, and Asp215. The 3ʹ-hydroxyl group of the primer strand is 
within hydrogen bonding distance of Glu/Gln84, corresponding to Glu357 of Klenow, which  
Figure 7. Structure corresponding to atypical regions of the polymerase domain. Klenow (gray, PDB 1KLN) 
is superimposed onto apPOL (blue) in Panels a–c. (a) Six amino acids (dark blue) extend Helix O1 of apPOL 
relative to that of Klenow. (b) apPOL (blue) lacks six amino acids (light gray) found in Klenow. (c) The 
connection from Strand 11 to Helix Q is shortened by 11 residues in apPOL relative to Klenow. (d) 
Superposition of apPOL (blue) onto T7 [purple, PDB 1ZYQ (40)] shows a short Helix Q in T7, and also an 
additional loop before Strand 10. (e) Superposition of apPOL (blue) onto polγ [yellow, PDB 3IKM (41)] 
reveals a vastly different structure between Strand 11 and Helix Q. 
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hydrogen bonds with the 3ʹ-hydroxyl group and a metal ion (46). Leu361 in Klenow is in direct 
contact with the base at the 3ʹ-end of the primer strand and maps to Leu88 in apPOL. However, 
Phe473 of Klenow does not align with a corresponding residue in the sequence of apPOL, but 
comes close (~4 Å) to Trp199. The two active site sulfates of the N-apPOLexo− (PDB 5DKT) are 
within 2 Å of the phosphoryl groups of the docked DNA primer strand. 
In the polymerase editing complex, attention has historically focused on the 3ʹ-end of the 
DNA primer. The DNA template strand, however, binds to a site distinct from that in the DNA 
complex at the polymerase active site (Figure 6). The template DNA docks onto the 
electropositive surface that extends around apPOL between the finger subdomain and the 
exonuclease domain (Figure 5a), suggesting the possibility of extended protein-template  
interactions. This additional electropositive surface, coupled with the electropositive surface 
along the phosphodiester backbone of the primer strand, implies a stable editing complex. 
Kinetics experiments revealed an unusually stable complex in apPOL due to the 
misincorporation of a triphosphate nucleoside (11). 
Atypical regions 
Three sequence motifs define the atypical A-family polymerase (15); however, only two 
motifs map to divergent structure. The first motif (481YANTYYG486 in apPOL) extends  
Helix O1 (Figure 7a). Tyrosines 481, 485, and 486, conserved within the atypical A-family, point 
toward the base moieties of template DNA and nucleoside triphosphate. Mutation of Tyr481, 
Tyr485, and Tyr486 to alanine (N-apPOLexo‒/Y481A/Y485A/Y486A) results in a 3-fold decrease in 
Table 2. Kinetic parameters of P. falciparum apicoplast DNA polymerase constructs 
    
  Kd,DNA (nM) Apparent-Km,dNTPs (nM) Vmax (nM*min-1) 
N-apPOLexo− 38 ± 3 100 ± 30 6.6 ± 0.5 
N-apPOLexo−/Y481A/Y485A/Y486A 160 ± 30 25 ± 10 1.4 ± 0.1 
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polymerase activity, a 4.5-fold increase in kd-DNA, and a 4-fold decrease in apparent-Km,dNTP 
(Table 2). The opposite effect on kd-DNA and apparent-Km,dNTP due to mutation suggest binding 
antagonism (direct or indirect) between the dNTP and primer/template DNA. Evidently, these 
helix-extending tyrosines stabilize the binding of DNA primer/template at the expense of dNTP 
binding affinity. Interestingly, human polγ has a five-residue extension of Helix O1. However, 
the residue types do not match those of apPOL. 
The second motif shortens the loop from Helix J to Helix K in the palm subdomain. 
Typical A-family polymerases have a six-residue loop, whereas apPOL connects helical 
elements with two residues 390‒391 (Figure 7 and Figure 3). The six-residue loop includes a 
conserved arginine and glycine (positions 682 and 686, respectively in Klenow). Conceivably 
Arg390 of apPOL corresponds to Arg682 of Klenow which is involved in contacting duplex 
DNA. The third atypical region, an insertion of two amino acids (523QY524), results in no 
secondary structural differences between apPOL and the typical A-family polymerases. A two-
residue deletion at the N-terminal end of Helix P compensates for the insertion located on Strand 
10 of the finger subdomain. 
The structure of apPOL reveals another difference relative to Klenow, BF, and Taq that 
was not previously recognized on the basis of sequence analysis. An eleven-residue deletion in 
apPOL eliminates an extended loop between Strand 11 and Helix Q, as well as residues from the 
N-terminal end of Helix Q (Figure 7c). The sequence deletion, which is conserved in atypical A-
family polymerases, may be responsible for a shortened Helix P and the aforementioned 
conformational displacements of helices of the finger subdomain. These structural differences 
are in proximity to the 5ʹ-overhang of the template DNA strand (Figure 6a). Arg784 in BF (836 
in Klenow) is absent in apPOL, and Ser717, Tyr719, and Arg789 in BF correspond respectively 
64 
to Asn474, Val476, and Thr540 in apPOL. These residues in BF and Klenow interact with the 5ʹ-
overhang of the DNA template strand in its primer-extension binding mode (20), 43). T7 DNA 
and polγ polymerases also have shortened Q helices. However, other elements of secondary 
structure fill the void (Figure 7d, e). In spite of the altered structure, N- and C-apPOLexo‒ binds 
primer/template DNA with a kd-DNA of 38 ± 3 and 23 ± 2 nM respectively, comparable to other 
stable protein/DNA complexes. The potential loss of DNA-interacting residues in this loop may 
be compensated for by the triple tyrosine insertion loop. 
A 50-residue extension to the N-terminal side of the exonuclease domain is the most 
apparent difference between apPOL and other A-family members (Figure 3 and Figure 8). 
Residues in the NTR are exclusive to and highly conserved within the Plasmodium genus and 
may be necessary for a properly functioning polymerase (11, 22). The NTR has a short helical 
region followed by two anti-parallel β-strands (Strand 1A and Strand 1B). The antiparallel strands 
Figure 8. Plasmodium N-terminal region. A network of hydrogen bonds and hydrophobic interactions connects 
the NTR of apPOL to the exonuclease domain. The residues involved in these interactions are highly conserved 
across Plasmodium spp. 
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extend the central β-sheet of the exonuclease domain. However, Strand 1B connects to Strand 1 
through only two main-chain hydrogen bonds. Additional hydrogen bonds are between Strand 1B 
and residues 202 to 206 of a long loop (residues 170 to 206) that covers the exonuclease active 
site and extends to the palm subdomain. Hydrophobic interactions between the NTR and the rest 
of the exonuclease domain suggest a stable interface that is unlikely to separate. Moreover, the 
interface between the NTR and exonuclease domain proper is invariant over three independent 
polypeptide chains subject to different lattice contacts and conditions of crystallization. The 12-
residue β-strands of the NTR coil into a right-handed helix similar to the β-hairpin structures of 
the Arc and MetJ repressors. The hairpin structures of Arc and MetJ repressors bind to the major 
groove of duplex DNA (49). NTR-DNA interactions could increase the intrinsic processivity of 
apPOL, as an extrinsic processivity factor for apPOL has not been identified. 
Deletion of the NTR (C-apPOL52–628) significantly decreases expression levels (20-fold 
less relative to wild-type), purity, and protein stability. Identification of C-apPOL52–628 on gels 
employed Western blot analysis (Figure 9a) and densitometry analysis of Coomassie-stained gels 
determined the percent purity of the enriched protein (Figure 9b). Low enzyme purity confounds 
assays for DNA binding and pre-steady state kinetics. However, we captured reliable results 
from steady-state kinetics of enriched proteins. Preparations of exonuclease deficient C-
apPOL52–628/exo– and exonuclease and polymerase deficient C-apPOL52–628/exo–/pol– determined 
levels of exonuclease and polymerase contamination in C-apPOL52–628. C-apPOL52–628/exo–/pol– 
had no detectable polymerase activity, indicating no measurable polymerase contamination in 
preparations of C-apPOL52–628. Therefore, at saturating DNA (400 nM) and dNTP (16 μM), the 
observed specific activities of 0.04 s-1 and 0.03 s-1 for C-apPOLexo– and C-apPOL52–628/exo–, 
respectively, suggest little or no effect on polymerase activity due to NTR deletion. No 
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exonuclease activity is observed for N-apPOLexo−. Exonuclease activities of C-apPOL52–628 and 
C-apPOL52–628/exo– are similar and less than that of C-apPOL52–628/exo–/pol– (Figure 9c), suggesting 
exonuclease activity is severely affected by the NTR deletion and that observed exonuclease 
activity comes from contaminants. Hydrophobic interactions and a network of hydrogen bonds 
connect the NTR to the exonuclease domain (Figure 8). Removal of the NTR disrupts these 
interactions and likely results in an unstable or misfolded exonuclease domain.  
Figure 9. Evaluation of C-apPOL52-628 purity and activity. (a) Western blot analysis of C-apPOL (lanes 1 and 3) 
and C-apPOL52-628 (lane 2 and 4). Membrane transfer visualized through Ponceau S staining (lanes 1 and 2). Rabbit 
polyclonal antibodies generated to apPOL specifically interact with apPOL constructs (lanes 3 and 4). (b) SDS-
PAGE of C-apPOL (lane 1), C-apPOL52-628 (lane 2), C-apPOL52-628/exo− (lane 3), and C-apPOL52-628/exo−/pol− (lane 4) 
stained with Coomassie. ImageQuant TL (GE Healthcare) was used to determine percent purity of target protein. 
(c) Exonuclease activity of N-apPOL (blue), C-apPOL52-628 (green), C-apPOL52-628/exo− (purple), and C-apPOL52-
628/exo−/pol− (orange). 
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Potential for Drug Discovery 
DNA polymerases of HIV, herpes simplex virus, hepatitis B virus, and cytomegalovirus 
are targets of therapeutic drugs, the majority of which are nucleoside-based (50). Such drugs, 
although effective inhibitors, often lack selectivity due to the conservation of polymerase active 
sites. The optimization of lead compounds, guided by structure, however, has yielded potent 
non-nucleoside and uncompetitive inhibitors against HIV reverse transcriptase (13). The 
structure of apPOL reveals attributes that may facilitate structure-guided drug design. 
MetaPocket (51), a software predictor of potential ligand binding sites, correctly identifies the 
polymerase and exonuclease active sites, and six other potential ligand binding sites. Four of the 
six sites are in the exonuclease domain and two are in the polymerase domain (Figure 10). A 
similar analysis of polγ reveals no pockets corresponding to those of apPOL. Moreover, Malaria 
Box (52) compound MMV666123 inhibits polymerase activity of apPOL (IC50 of ~700 nM), and 
preferentially goes (on the basis of in silico analysis) to one of the potential ligand binding sites 
on apPOL. Hence, the structure of apPOL offers a point of departure in the design and discovery 
of specific inhibitors through computer docking and co-crystallization experiments. 
The benefits of a new drug targeting the apicoplast of P. falciparum and related 
organisms could transcend those of the typical rapid elimination of an invading organism. 
Inhibition of apicoplast genome replication, transcription, and/or translation results in the 
“delayed death” of the organism (53). In the presence of inhibitors of apicoplast topoisomerase, 
parasites grow, divide, and produce daughter cells that die instead of establishing productive 
infections (54). The delayed death phenotype occurs in both the red blood cell and liver stages of 
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infection, and timely treatment of liver infection results in daughter parasites that cannot 
establish a productive blood cell infection (55). Mice exposed to live sporozoites simultaneously 
with apicoplast inhibitors exhibit no infection of red blood cells and acquire immunity to 
subsequent infections with live sporozoites. The delayed death phenotype may extend to the 
sporozoite, which would block transmission of the disease from human to mosquito (56). Hence, 
effective drugs targeting the apicoplast may facilitate a mechanism of natural immunization 
toward the most prevalent infectious disease known to human civilization. 
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CHAPTER 4 
A HIGH-THROUGHPUT ASSAY TO IDENTIFY INHIBITORS OF THE APICPLAST DNA 
POLYMERASE FROM PLASMODIUM FALCIPARUM 
Morgan E Miller, Eric E Parrott, Risham Singh, and Scott W Nelson 
Modified from a paper published in Journal of Biomolecular Screening (2014). 19(6): 966-972. 
Abstract 
Infection by Plasmodium falciparum is the leading cause of malaria in humans. The 
parasite contains a unique and essential plastid-like organelle called the apicoplast that, similar to 
the mitochondria and chloroplast, houses its own genome that must undergo replication and 
repair. The putative apicoplast replicative DNA polymerase, POM1, has no direct orthologs in 
mammals, making the P. falciparum POM1 an attractive antimalarial drug target. Here, we 
report on a fluorescent high-throughput DNA polymerase assay that relies on the ability of 
POM1 to perform strand-displacement synthesis through the stem of a DNA hairpin substrate, 
thereby separating a Cy3 dye from a quencher. Assay-validation experiments were performed 
using 384-well plates and resulted in a signal window of 7.90 and a Zʹ factor of 0.71. A pilot 
screen of a 2880-compound library identified 62 possible inhibitors that cause more than 50% 
inhibition of polymerase activity. The simplicity and statistical robustness of the assay suggest it 
is well suited for the screening of novel apicoplast polymerase inhibitors that may serve as lead 
compounds in antimalarial drug-discovery efforts.  
Introduction 
More than 3 billion people live in areas at risk of malaria, and the disease causes an 
estimated 650,000 deaths per year worldwide (1). The majority of these deaths occur in African 
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children younger than age five. Malaria is caused by parasites of the genus Plasmodium, mainly 
P. falciparum and P. vivax, with the former being the most common and most deadly (2). 
Plasmodium is in the phylum Apicocomplexa, the members of which are exclusively animal 
parasites and are responsible for several human and agricultural diseases, such as toxoplasmosis 
(Toxoplasma gondii), babesiosis (Babesia bovis), cyclosporiasis (Cyclospora cayetanensis), and 
coccidiosis (Eimeria falciformis). All of these organisms contain an unusual organelle called the 
apicoplast (3). The apicoplast is evolutionarily related to a chloroplast and was obtained through 
a secondary endosymbiotic event with red algae (4). The apicoplast has lost its photosynthetic 
ability, but it has retained the biochemical pathways for the synthesis of isoprenoids, fatty acids, 
and heme, along with iron–sulfur cluster assembly (5). The parasite has come to completely rely 
on the apicoplast for production of isoprenoids (6). This dependent relationship has brought a 
great deal of attention to the apicoplast and its potential as a drug target (7). 
Because the apicoplast is derived from a chloroplast, it contains its own genome and 
harbors the proteins necessary for DNA replication, transcription, and translation (8). At 35 kb, 
the genome is greatly reduced compared to the chloroplast. Although many of the proteins 
required for transcription and translation are encoded by the apicoplast genome, all of the DNA 
replication proteins are encoded in the nuclear genome and are imported into the apicoplast 
following translation. Inhibition of apicoplast replication, transcription, and translation with 
antibiotics such as tetracycline and ciprofloxin causes a phenomenon referred to as the “delayed-
death” phenotype (8). When treated with these antibiotics, parasites continue to grow, divide, 
and produce daughter cells that die instead of establishing productive infections. Although the 
biological basis of this delayed-death phenotype is poorly understood, it clearly establishes the 
apicoplast as a target of drug action. 
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 The apicoplast DNA polymerase (POM1; hereafter referred to as apPOL, or apPOLexo− 
for the exonuclease deficient mutant) represents an especially attractive target for antimalarial 
drug development. apPOL is clearly of prokaryotic origin, with its nearest homolog outside of 
Apicomplexa being the replicative polymerase from the cyanobacteria Cyanothece sp. PCC 8802 
(35% identity) (9). The most similar human DNA polymerases are the lesion bypass polymerases 
theta and nu (23 and 22%, respectively), with the other human DNA polymerases displaying < 
20% identity. In contrast, there is 84% identity between the apPOLs from the two primary 
causative agents of human malaria, P. falciparum and P. vivax, suggesting that drugs targeted 
against the P. falciparum apPOL would be effective in treating P. vivax infections as well. In 
addition, polymerases appear to be well suited to therapeutic inhibition because there are 
commercial drugs targeting the polymerases of HIV, herpes simplex virus, hepatitis B virus, and 
cytomegalovirus (9). 
Many assays for DNA polymerase activity have been reported, and several have been 
used in a high-throughput fashion. To facilitate the high-throughput screening for apPOL 
inhibitors, we have modified an established assay based on a molecular-beacon DNA substrate 
for use in high-throughput screening (10). We have used this assay in a continuous mode to 
determine kinetic parameters for apPOL and in a quenched-time mode for high-throughput 
screening of a small library of 2880 compounds. The assay proved to be statistically robust with 
a Z’ factor of 0.71, a signal window of 7.9, and a signal-to-background ratio of 41. Many 
potential small-molecule inhibitors were identified in the pilot screen. 
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Materials and Methods 
Materials 
The 33-mer DNA hairpin substrate (5ʹCCTCTCCGTGTCTTGTACTTCCCGTCAG-
AGAGG) containing either Cy3 or hexachlorofluorescein (HEX) dyes at the 5ʹ end, and either 
Iowa Black® FQ (IBQ) or Black Hole Quencher®-1 (BQ1) quenchers at the 3ʹ end were 
purchased from Integrated DNA Technologies. The hairpin contains a 6-nucleotide-long double-
stranded stem and 21-nucleotide- long single-stranded loop. A 9-nucleotide primer (5ʹ-
GACGGGAAG) that is complementary to a portion of the loop region was obtained from the 
Iowa State University DNA Facility. Nickel-agarose was bought from the Sigma- Aldrich 
Chemical Company, deoxyribonucleotides were acquired from Invitrogen or Sigma-Aldrich, 
chloroquine from Santa Cruz Biotechnology, and aurintricarboxylic acid (ATA) from Acros 
Organics. 
Purification of apPOLexo− 
The exonuclease-deficient apPOL (D1470N and E1472Q) was expressed and purified as 
previously described with a few exceptions (11). Cells were lysed in 20 mM Tris-HCl pH 8.0, 
500 mM NaCl, and 5 mM imidazole. Clarified lysate was loaded on ~5 mL of Ni-agarose resin 
and washed with 100 mL of 20 mM Tris-HCl pH 8.0, 500 mM NaCl, and 5 mM imidazole 
followed by a high-salt wash of 100 mL of 20 mM Tris-HCl pH 8.0, 1 M NaCl, and 25 mM 
imidazole. Protein was then eluted in a minimal volume of elution buffer containing 20 mM Tris-
HCl pH 8.0, 500 mM NaCl, and 150 mM imidazole. The resulting protein was then further 
purified through size exclusion chromatography using a 320 mL HiLoad 26/60 Superdex 200 
equilibrated in 20 mM Tris-HCl pH 8.0 and 400 mM NaCl. 
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Kinetic Assays 
The enzymatic activity of apPOLexo− was determined using the DNA hairpin substrate 
containing the Cy3 and BQ1 dye-quencher pair (Figure 1A). The reactions were carried out at 25 
°C in 20 mM Tris-HCl pH 8.0, 10 mM MgAc, 50 mM KAc, 1 mM DTT, 0.1 mg/ml BSA, and 
Figure 1. Polymerase activity with the high-throughput DNA substrate. (A) A schematic of the DNA substrate 
and the steps leading to an increase in fluorescence. Additional details can be found in the text. (B) The 
increase in fluorescence signal is dependent on protein concentration. A polymerase concentration of 3 nM 
was determined to be optimal for high-throughput screening because approximately half of the DNA substrate 
would be consumed after 7.5 minutes. The dotted line represents 1 nM apPOLexo−, the short dashed line 2 nM 
apPOLexo−, the large dashed line 4 nM apPOLexo−, and the solid line 8 nM apPOLexo−. The inset is a plot of 
the initial velocities versus enzyme concentration. The slope of the line represents the apparent-kcat, which is 
4.95 min−1. (C) Denaturing urea–polyacrylamide gel analysis of product formation using 32P-labeled primer. 
The unextended primer and fully extended product are marked by arrows at the bottom and top of the gel, 
respectively. (D) Overlay of polymerase activity based on polyacrylamide gel analysis (♦) and fluorescence 
assay using the hairpin substrate (gray line). 
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2% DMSO, and all data were collected on a Cary Eclipse Fluorescence Spectrophotometer using 
the Cary Kinetics software at an excitation wavelength of 545 nm and an emission wavelength of 
570 nm. 
To validate that the Cy3 dye was not affecting the rate of apPOLexo− polymerization, two 
separate reactions were carried out with 3 nM apPOLexo−, 16 µM deoxynucleoside triphosphates 
(dNTPs) (~5× the KM), and 50 nM DNA substrate (which provided a strong fluorescent signal). 
In the first reaction, polymerase activity was determined on a Cary Eclipse, as stated above. For 
the second reaction, the primer that is annealed to the hairpin DNA was radioactively labeled 
with 32P using T4-polynucleotide kinase (New England Biolabs). The reaction was initiated by 
mixing equal volumes of apPOLexo− and a mixture containing dNTPs and DNA. Time points 
were then removed and quenched with 0.1 M ethylenediaminetetraacetic acid (EDTA) and 80% 
(v/v) formamide. Each time point was analyzed using a 16% denaturing polyacrylamide gel 
containing 7.5 M urea in a Tris-borate-EDTA buffer. The gel was visualized using a FujiFilm 
FLA-5100 Fluorescent Image Analyzer and analyzed using ImageJ (National Institutes of 
Health, Bethesda, MD). 
To determine the optimum enzyme concentration and time point for the stopped-time 
high-throughput assay, the concentration of apPOLexo− was varied from 0 to 8 nM. It was found 
that for a reaction containing a final concentration of 16 µM dNTPs and 50 nM DNA substrate, 3 
nM apPOLexo− led to 50–90% of substrate use over a time course of 7.5 minutes (a convenient 
time for the HT robotic platform). The steady-state kinetics values (KM for nucleotide and the 
DNA substrate) were established using 20 nM apPOLexo−. To determine the KM-DNA, the 
nucleotide concentration was held at 16 µM while the DNA concentration was varied from 0 to 
800 nM. To determine the KM-dNTPs, the DNA concentration was held at 50 nM and the 
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nucleotide concentration was varied from 0 to 16 µM. Initial rates were analyzed using the 
Matlab R2011b software (Mathworks) using the standard Michaelis-Menten equation. 
ATA was identified through high-throughput screening as an inhibitor of apPOLexo−. 
Although ATA has previously been classified as an inhibitor by mimicking DNA, recent studies 
have shown that this may not always be the case (12). For this reason, ATA was selected for 
further kinetic studies. The IC50 of ATA was determined using 16 µM dNTPs, 50 nM DNA 
substrate, 3 nM apPOLexo−, and varying concentrations of ATA from 0 to 12 µM. ATA was 
incubated with apPOLexo− in the absence of DNA and nucleotide for several minutes prior to the 
start of the reaction. The reaction was initiated by simultaneous addition of DNA and dNTPs, 
and time courses lasted approximately 15 minutes. The slope of the linear portion of the time 
course was used to determine the initial velocities. The resulting initial velocities were fit with 
the Matlab R2011b software (Mathworks) using the following equation: 
𝑉𝑉0 = 𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚
1+
𝐼𝐼
𝐼𝐼𝐼𝐼50
    Equation 1 
 
where Vo represents initial velocity, Vmax represents maximum velocity, I is the ATA 
concentration, and IC50 is the concentration of ATA that produces 50% inhibition. 
Determination of the ATA inhibition mechanism was carried out by incubating 20 nM 
apPOLexo− with varying concentrations of ATA for several minutes. To establish the inhibition 
mechanism versus nucleotides, the DNA substrate was held constant at 50 nM, and the dNTPs 
were varied from 0 to 16 µM. To establish the inhibition mechanism versus DNA, the nucleotide 
was held constant at 16 µM nucleotides, and the DNA substrate was varied from 0 to 800 nM. 
The resulting data were fit against inhibition models describing competitive, noncompetitive, 
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mixed, and uncompetitive inhibition using the Dynafit (13) software. The best-fitting model was 
determined using the model discrimination analysis function in the Dynafit software. 
Validation Assay and Pilot Screen 
The validation assay was performed at the University of Iowa High Throughput 
Screening Facility. The reaction was carried out with a final concentration of 16 µM dNTPs, 50 
nM DNA substrate, and 3 nM of apPOLexo− in 20 mM Tris-HCl pH 8.0, 10 mM MgAc, 50 mM 
KAc, 1 mM DTT, 0.1 mg/mL BSA, and 2% DMSO in the presence and absence of 8 mM 
chloroquine. Solutions were loaded into a Nunc 384-well plate (Thermo Scientific) using a 
MicroLab Pipettor (Hamilton). A 2× protein solution was incubated with 16 mM chloroquine (8 
mM final) when applicable, and then mixed with an equal volume of 2× DNA solution to initiate 
the reaction. After 7.5 minutes at room temperature, the reaction was quenched with 100 mM 
EDTA. Fluorescence was detected at 545 nm using an Envision High Throughput Plate Reader 
(Perkin Elmer). Resulting data were analyzed and evaluated for robustness through 
determination of the signal window and Zʹ (14,15). Maximum signal values are those resulting 
from reactions containing no inhibitors, and minimum signal values are background readings 
with no fluorescent substrate controls. 
A 2880-small-molecule pilot screen composed of the Spectrum Collection (composed of 
2320 compounds) and University of Iowa Legacy Collection (composed of 560 compounds) was 
carried out at the University of Iowa High Throughput Screening Facility. The screen took place 
under the same conditions as the validation assay with a 2× protein solution being incubated with 
20 µM (10 µM final) small molecules. Small molecules were added using a Star Robotic Liquid 
Handler System (Hamilton). Controls containing no protein, 8 mM chloroquine, and no small 
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molecules were performed on each 384-well plate. Fluorescence was detected at 545 nm using 
an Envision High Throughput Plate Reader. Resulting data were analyzed using Microsoft Excel. 
Results and Discussion 
Purification of apPOLexo− 
The expression of apPOLexo− is extremely robust with yields approaching 50 mg of pure 
protein per liter of Luria broth. The purified protein is stable at room temperature for up to 8 
hours and for at least 1 year frozen at −80 °C. The enzyme is also highly active (11), enabling a 
very small amount of protein to be used in each assay (3 nM). In the 384-well format, a single 
preparation of protein from 1 L of media is adequate to screen more than 13,000 plates. 
Fluorescence Assays 
The hairpin DNA substrate used here was previously developed by others but contained a 
carboxytetramethylrhodamine (TAMRA) fluorophore and a Dabcyl quencher (10). The substrate 
was used in a continuous DNA polymerase assay in a lowthroughput fashion (Figure 1A) (10). 
Although the assay, as previously reported, is suitable for continuous assays, because of 
incomplete quenching of the TAMRA dye fluorescence by the Dabcyl quencher, the signal-to-
background ratio is relatively low (~fivefold) and is borderline for high-throughput screening. 
For this reason, we attempted to find a better fluorophore-quencher pair. We initially replaced 
the pair with hexachlorofluorescein and the Iowa Black® RQ quencher, but saw only modest 
improvements in the statistical parameters. Using 96-well plates, this dye-quencher pair resulted 
in a signal window of ~6.6, a Zʹ factor of 0.60, and a signal-to-background ratio of 7.1. We then 
tried the Cy3 fluorophore and BQ1 quencher pair, which resulted in better statistical parameters. 
Using 96-well plates, the Cy3-BQ1 dye-quencher pair resulted in a signal window of ~8.9, a Zʹ 
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factor of 0.73, and a signal-to-background ratio 
of 9.7. Because some proteins have a strong 
affinity for dye molecules, we confirmed that the 
observed rate was linearly dependent on the 
concentration of apPOLexo− concentration. As 
seen in Figure 1B, the increase in fluorescent 
signal is proportional to the amount of apPOLexo− 
in the reaction, with an apparent-kcat of 4.95 
min−1. To directly compare the increase in 
fluorescence signal to extension of the primer, 
we 32P labeled the primer strand of the substrate 
and analyzed the polymerase time course using 
denaturing urea-polyacrylamide gel electrophoresis 
(Figure 1C). Comparison of the fluorescence signal 
with the quantification of the gel indicates that the 
increase in fluorescence is directly proportional to 
the amount of primer extended (Figure 1D). The gel analysis also indicates that there is some 
degree of pausing when apPOLexo− reaches the stem portion of the substrate, where it must 
perform strand-displacement synthesis to separate the fluorophore from the quencher. We then 
used the assay in continuous mode to determine the steady-state kinetic parameters of apPOLexo−, 
which resulted in apparent-KM values of 3.4 ± 1.0 µM and 305 ± 99 nM for dNTPs and DNA, 
respectively (Figure 2). These values are in close agreement with those determined using the 
standard 32P-labeled primer-extension assay (11). 
Figure 2. Steady-state kinetics of apPOLexo−. The 
fluorescent hairpin substrate was used, and initial 
rates were determined from continuous time 
courses. The initial rates (points) were fit to a 
steady-state mechanism, and the best fit is 
represented by the line. (A) A KM value of 3.4 μM 
was determined for nucleotide. (B) The KM value of 
305 nM was determined for the hairpin substrate. 
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High-Throughput Assay and Pilot Screen 
Following the tests using 96-well plates, the assay was validated for high-throughput 
screening using 384-well plates. Half of the plate was used as a minimum signal reference (8 
mM chloroquine and 3 nM polymerase), and the other half was used as the maximum signal 
control (3 nM polymerase added). The reactions were initiated by the addition of DNA and 
nucleotide, and all wells were quenched with EDTA after 7.5 minutes. The plates were analyzed, 
and resulting values for the signal window, Zʹ factor, and signal-to-background ratio were 
determined to be 9.27, 0.71, and 17.96, respectively. 
We next performed a pilot screen using the Spectrum Collection and the University of 
Iowa Legacy Collection (Figure 3). The screen consisted of nine 384-well plates with the first 
two columns of each plate reserved for reference wells (no polymerase addition), the upper half 
of the last two columns for the fully inhibited reaction (8 mM chloroquine), and the lower half of 
the last two columns for the uninhibited reaction (polymerase addition only). The average 
fluorescent signals from the fully active and inhibited reactions were 1638 ± 143 (signal-to-noise 
Figure 3. High-throughput pilot screen. The small-molecule pilot screen of the Spectrum Collection (2320 
compounds) and the University of Iowa Legacy Collection (560 compounds) resulted in 62 hits that inhibit 
polymerase activity by at least 50%. No polymerase controls (gray X’s that occur periodically near the bottom 
of the graph) were performed on each of the nine 384-well plates. Each symbol type represents the results from 
an individual 384-well plate. 
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of 11) and 39 ± 14 (signal-to-noise of 2.8), respectively. These data were used to calculate values 
for the signal window, Zʹ factor, and signal-to-background ratio of 7.9, 0.71, and 42, 
respectively. The increase in the signal-to-background ratio compared to the initial 
characterization is due to an optimization of the plate-reader photomultiplier voltage prior to 
fluorescence acquisition. 
The pilot screen identified 62 compounds that resulted in a fluorescence signal of less 
than 700 (i.e., causing more than 50% inhibition), giving a hit rate of approximately 2.1%. 
Among these 62 compounds were several nonspecific inhibitors of nucleic acid enzymes, such as 
DNA intercalators (e.g., ethidium bromide, epirubicin, and acriflavine) and known or suspected 
DNA mimics (16) (e.g., suramin and ATA). It is expected that nonspecific inhibitors can be 
removed by using this assay to perform counterscreens against a panel of selected DNA 
polymerases (e.g., Escherichia coli Pol I and human pol γ). In addition to removing compounds 
that act as DNA intercalators and mimics, the counterscreens would also identify compounds that 
may be interfering with the fluorescent signal of the DNA substrate and/or product. 
Alternatively, an orthogonal assay similar to the one shown in Figure 1C could be used to rule 
out dye interference. 
ATA was selected for determination of its inhibition mechanism because it appears to be 
capable of multiple inhibition mechanisms depending on the enzyme it is acting on. Although it 
is generally assumed that the ATA polymerizes and acts as a nonspecific DNA mimic15 (i.e., 
competitive with DNA), recent studies using HCV helicase found that ATA was competitive 
with adenosine triphosphate and noncompetitive with DNA (12). To determine the inhibition of 
ATA for apPOLexo−, we first measured the dose–response of ATA under our standard assay 
conditions and determined the IC50 to be 0.9 ± 0.2 µM (Figure 4A). We then determined the 
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inhibition mechanism of ATA against dNTPs. The concentrations of ATA and dNTPs were 
varied above and below their IC50 and KM, respectively, and the resulting data were fit to a 
variety of inhibition mechanisms using the Dynafit software (13). The best-fitting mechanism for 
ATA versus dNTPs was true noncompetitive with Ki-ATA and KM-dNTPs values of 0.99 ± 0.08 
µM and 3.6 ± 0.5 µM, respectively. 
We also determined the inhibition mechanism of ATA against the DNA substrate. Again, 
the concentrations of ATA and DNA were varied, and the data were fit to several possible 
inhibition mechanisms. The best-fitting mechanism was true noncompetitive with a K-ATA and 
KM-DNA of 1.47 ± 0.09 µM and 261 ± 15 µM, respectively. Because the inhibition mechanism 
of ATA is true noncompetitive against both dNTPs and DNA (i.e., the binding of ATA does not 
affect the apparent-KM’s for the substrates), the two determined Ki’s and the IC50 values should 
Figure 4. Mechanism of aurintricarboxylic acid (ATA) 
inhibition. (A) The IC50 of ATA was determined by the 
percentage of polymerase activity (♦) at variable 
concentrations of ATA in mM. Data were fit to the standard 
IC50 equation (Eq. 1), and an IC50 of 0.9 mM was determined. 
The inset image depicts the structure of ATA. (B) Plots of 
initial velocity versus dNTPs concentration at various 
concentrations of ATA. ATA concentrations are 0 uM (■), 2 
uM (●), and 4 uM (♦). The solid lines are theoretical fits to a 
noncompetitive mechanism using values given in the text. 
(C) Plots of initial velocity versus DNA concentration at 
various concentrations of ATA. ATA concentrations are 0 
uM (■), 2 uM (●), and 4 uM (♦). The solid lines are 
theoretical fits to a noncompetitive mechanism using values 
given in the text. 
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be the same. We have determined values of 0.90, 0.99, and 1.47 µM for the IC50, Ki (against 
dNTPs), and Ki (against DNA), respectively, which are all in reasonable agreement with each 
other. In addition, the apparent-KM values determined using the data shown in Figure 2 
correspond very well to the KM values determined using the data in Figure 4B and Figure 4C (3.4 
and 3.6 µM for KM-dNTPs and 305 and 261 nM for KM-DNA, respectively). Based on this 
analysis, it appears that in the case of apPOLexo−, ATA is not acting simply as a DNA mimic, but 
binds to the enzyme at a unique site that does not directly overlap with either the nucleotide- or 
DNA-binding site. 
In conclusion, we have improved on a previously developed DNA polymerase assay by 
altering the fluorophore and quencher pair, thereby increasing its dynamic range. We found that 
the assay provides steady-state kinetic parameters that are comparable to the traditional 32P-based 
assay and is both highly sensitive and reproducible using 96- and 384-well plates. A pilot screen 
resulted in excellent statistical parameters (Zʹ factor and signal window) and identified a 
number of potential inhibitors of the apPOLexo− DNA polymerase. We used the assay to 
determine the kinetic inhibition mechanism of ATA and somewhat unexpectedly found that it 
was not behaving as a DNA mimic but was noncompetitive against both dNTPs and DNA. The 
robustness of the modified assay strongly suggests that it is well suited to the screening of much 
larger small-molecule libraries in an effort to identify inhibitors of the P. falciparum apicoplast 
DNA polymerase that can serve as lead compounds in antimalarial drug-discovery efforts. 
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CHAPTER 5 
CONCLUSIONS 
Conclusions 
We have only just begun to understand the P. falciparum apicoplast DNA polymerase, 
apPOL, and its role in replication and repair of the apicoplast genome. In this dissertation, I 
presented the crystal structure of apPOL, the first atypical A-family DNA polymerase to be 
structurally characterized, and provided insight into a poorly characterized subfamily. Before we 
can develop drugs to inhibit the apicoplast polymerase in a highly potent and specific manner, a 
deeper understanding of the structure and mechanisms of apPOL is required. This crystal 
structure provides a starting point for structure-aided anti-malarial drug design, and will assist in 
the biochemical characterization of apPOL. 
As discussed in chapter one, the apicoplast DNA polymerase is expressed as a 
polyprotein, Prex, containing primase, helicase, and polymerase subdomains. It has been clearly 
shown that Prex is targeted to the apicoplast where it undergoes post translational modification 
which may separate these three subdomains, though the degree of separation is unclear. (1–3). 
Despite having been identified in 2005, it is still uncertain where Prex is cleaved and what 
proteins are involved in its processing. 
Based on sequence alignment of Plasmodium Prex genes, it is likely that our apPOL 
construct is representative of functional replicative polymerase within the apicoplast (4). apPOL 
surpasses other Prex polymerase constructs in both activity and recombinant expression levels 
(1,5). While the protease responsible for cleaving the polymerase domain of Prex from the 
primase and helicase domains is still unknown, apPOL folds into a well ordered protein. The 
crystal structure shows ordered density for all N-terminal residues in our construct, and that the 
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extreme N-terminus residues form an ordered region involved in many stabilizing interactions. 
While we have not investigated the effect what additional upstream residues could have on 
polymerase activity, removal of the N-terminal region has a negative impact. As described at the 
end of chapter three, deletion of the N-terminal region results in a 20-fold decrease in 
polymerase expression and affects exonuclease activity, suggesting that this region is important 
for proper protein function.  
The structure of apPOL provides substantial information regarding the structural 
significances of the signature motifs that distinguish atypical A-family members (6). Two of the 
three signature motifs manifest as structural differences when apPOL is compared to typical A-
family polymerases from E. coli Pol I (Klenow), B. stearothermophilus, and T. aquaticus (Taq). 
One motif involves the deletion of a loop at the base of the thumb subdomain. This loop has been 
shown to be involved in the binding of the double stranded primer DNA and polymerase fidelity 
(7). It is possible that this absence of this loop in apPOL accounts for some of the differences in 
its fidelity as compared to Klenow. Further investigation of this motif could provide insight into 
the fine-tuning of DNA binding and polymerase fidelity. 
The second motif to show significant structural differences is a six amino acid addition 
which extends a helix at the tip of the finger subdomain. The most notable feature of this motif is 
three tyrosine residues at the end of the helix, pointed inwards towards the polymerase active 
site. Mutation of these tyrosines to alanines affects apPOL’s DNA binding affinity, nucleotide 
binding affinity, and rate of polymerization. Due to its close proximity to the single stranded 
template DNA binding site, it is possible that this motif is involved in positioning the template 
DNA. Removal of the tyrosines may cause a conformational change in the DNA which prevents 
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proper Watson-Crick base pairing with the incoming nucleotide, or positioning the 3ʹ-OH in a 
suboptimal location for chemistry. 
A key structural difference between apPOL and typical A-family members that was not 
identified through previous sequence alignment is the deletion of eleven residues at the base of 
the finger subdomain. These residues comprise the end of a large helix and a loop which contain 
many residues involved in binding template DNA (8,9). In typical A-family members, this helix 
and loop form a groove at the base of the finger subdomain where the template DNA is threaded 
through (10). Removal of this region provides a much more open interface for DNA to bind on 
apPOL. Even without this loop, apPOL is still able to bind DNA with an affinity comparable to 
other replicative DNA polymerases. It is possible that the tyrosine signature motif mentioned 
above compensates for this missing region, providing apPOL with the necessary interactions to 
position DNA into the active site. 
Information about the structure and biochemistry of these atypical regions of apPOL will 
aid in the development of potent inhibitors which are specific to apPOL. To identify compounds 
that inhibit apPOL, we developed a fluorescence-based assay that can be used in a high-
throughput manner to screen large libraries of small molecules. The assay is simple and 
statistically robust, making it well suited for high-throughput screening. We have shown that the 
assay behaves as expected in solution, and can be used in a continuous and stop-time manner to 
determine polymerase activity. The assay has been effectively used to perform a pilot screen, and 
can be used to determine the mechanism of inhibition through steady-state kinetics methods. 
Future work will involve further exploration of the biochemical relevance of the apPOL 
atypical regions. We will express a polymerase construct which incorporates the palm deletion 
from Klenow (described in Chapter three), and test if polymerase fidelity has shifted in favor of a 
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more Klenow-like profile. We will also test the impact of this signature motif on DNA binding, 
nucleotide affinity, and exonuclease activity. A construct that adds the missing loop from the 
base of the finger subdomain (described in Chapter three) will also be created. If apPOL binds 
DNA in the same region as Klenow, adding in the missing eleven residues at the tip of the Q-
helix should significantly impact DNA binding in apPOL. Point mutations within the N-terminal 
region will help map the specific residues and interactions which are necessary for proper folding 
and exonuclease activity. Understanding the role these regions play in regulating polymerase 
activity will provide further knowledge regarding what separates atypical from typical A-family 
polymerases, and how these areas can be exploited for drug targeting. We also hope to obtain a 
crystal structure of apPOL with DNA bound into the active site. This could provide information 
about how the polymerase interacts with the DNA substrate, and if those interactions vary from 
typical A-family members. 
Future work will also include screening large libraries of small molecules to identify 
compounds that inhibit apPOL. Those compounds will then be counter screened for their 
specificity to apPOL, and a mechanism of inhibition will be determined. Cocrystallization with 
apPOL screens and testing the effects of point mutations that disrupt binding pockets on 
polymerase activity will be performed in order to map out the inhibitor’s binding site. This 
information will then be used by a collaborator to develop more potent and specific variations of 
the compound. Subsequent compounds will then be tested for effectiveness and kill rates within 
P. falciparum in blood culture. 
Overall, this work has and will continue to lead toward better understanding of some of 
the unusual features of the apicoplast DNA polymerase at a basic scientific level. It will also 
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provide the means for identifying and optimizing small molecules that inhibit the function of 
apPOL, which in turn will result in the development of potent antimalarial compounds. 
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